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Certain cancers, especially those occurring in the hematopoietic system, can be identified by their 
cell of origin, and share many similar properties and signaling pathways to their normal 
counterparts.  We use the hematopoietic system to interrogate the relationship between normal 
and neoplastic transformation.  This work aims to better understand the molecular mechanisms of 
disease transformation in hematologic malignancies and translate basic biology findings into 
potential clinical applications.   
 
To examine how normal hematopoiesis is perturbed, we investigated how low dose-rate radiation 
affected hematopoietic cells in a whole animal model, and uncover mechanisms to mitigate this 
adverse effect.  Although the effects of acute radiation exposure have been well studied for many 
years, it is likely that widespread life-threatening radiation incidents will occur in the form of 
lethal doses delivered at relatively low rates over protracted time periods.  We show that damage 
to hematopoietic progenitors and hematopoietic failure is a consequence of such radiation 
exposure.  In addition, the anti-malaria agent chloroquine can protect these hematopoietic 
progenitors by activating ATM, a key player in the DNA damage response pathway, thus 
enhancing overall survival.  We provide a mechanistic explanation and potentially viable 
prophylaxic therapy for protracted low dose-rate radiation induced death. 
 
The Hedgehog signaling pathway is highly conserved and important for development.  Though its 
role in normal hematopoiesis is controversial, it does not impact normal adult hematopoiesis.  
Hedgehog signaling is aberrantly regulated in many cancers, including several hematopoietic 
malignancies.  We found Hedgehog signaling to be upregulated in human secondary leukemias.  
 iii 
We hypothesize that Hedgehog signaling plays a role in disease progression and generated a 
novel transgenic mouse model of myeloid disease progression.  Conditional activation of 
Hedgehog signaling dramatically accelerated disease progression from a chronic 
myeloproliferative disorder initiated by an activating mutation in the FLT3 tyrosine kinase 
receptor to rapidly fatal acute myeloid leukemia.  Mice harboring both the FLT3-ITD (a 
commonly found mutation in adult AML) and SmoM2, (a constitutively active form of 
Smoothened) alleles died rapidly from AML caused by increased myeloid progenitor 
proliferation.  Pharmacologically inhibiting both Hedgehog and FLT3 pathways synergistically 
reduced leukemic growth and improved overall survival compared to targeting either pathway 
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CHAPTER 1: INTRODUCTION 
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Cancer – biology, clinical advances, challenges 
Cancer is characterized by the uncontrolled growth and spread of abnormal cells, and is the 
second most common cause of death in the US.1  There have been significant efforts and progress 
at better diagnoses and more effective treatment in an attempt to eradicate cancer as a major cause 
of death, including understanding the biology of the disease.  However, several challenges still 
remain.  The biology of cancer is inherently complex – there are multiple changes and cellular 
interactions within a cell and in its surroundings that contribute to its transformation to an 
abnormal state.  There is also significant heterogeneity in disease across different organs and 
tissue systems, and a lack of suitable model organisms to accurately understand human disease.  
Furthermore, the lengthy drug development and approval process also pose as obstacles to getting 
new therapies to patients.   
 
Aims of thesis  
My goal is to investigate how normal cells transform to become abnormal in the development of 
cancer, and how we can interrupt this process to improve on treating the disease.  I am interested 
in studying this in the context of normal hematopoiesis and hematologic malignancies because 
hematopoietic development is a clearly delineated process, where cells can be identified and 
isolated at different stages of development and disease.  Additionally, by investigating 
mechanisms of disease transformation in this system, we can gain insights into how normal 
hematopoietic cells become abnormal resulting in aggressive disease, and translate these findings 
into potential clinical applications.  The next chapter summarizes the tools and technology we 
have to study normal and malignant hematopoiesis both in vitro and in vivo.  Chapter 3 shows 
how these tools are used to investigate perturbations to normal hematopoiesis during low dose-
rate radiation exposure, and describes how the anti-malaria drug chloroquine can play a unique 
role in mitigating this fatal damage to normal hematopoiesis.  Chapter 4 describes a novel mouse 
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model of myeloid disease progression and sheds light on the role of a developmental signaling 
pathway in disease.  Chapter 5 shows the clinical relevance of our findings in Chapter 4, and 
provides rationale for translating these pre-clinical findings into potential clinical applications.   
 
Hematopoiesis and Hematologic malignancies 
Hematopoiesis is defined as the formation of all types of blood cells from hematopoietic stem 
cells (HSCs) in the bone marrow.2 These cells include erythrocytes that provide oxygen carrying 
capacity, platelets that are crucial for hemostasis through blood clot formation, and leukocytes 
that maintain host defense to infections.  An inability to maintain the production of these 
circulating cells through regulating the proliferation, differentiation and maturation of immature 
progenitor cells will put an individual at risk for hematologic disorders.  HSCs maintain blood 
production in the adult by maturing into multipotent progenitors (MPP) that subsequently 
differentiate into lineage-committed common myeloid progenitors (CMP) and common lymphoid 
progenitors (CLP) that eventually produce mature blood cells.2, 3 This hierarchical production of 
blood cells from their progenitors is a well delineated process; we currently have the technology 
to identify and isolate hematopoietic stem and progenitor cells at various stages of development.  
Furthermore, HSCs undergo self-renewal that allows the maintenance of blood production over 
the lifetime of the organism.  In the development of leukemia, many of the features of normal 
hematopoiesis are retained.  Normal HSCs acquire genetic mutations and leukemogenic events 
that lead to malignant clonal expansion.  These dominant clonal populations retain the 
hierarchical organization found in normal hematopoiesis, however the leukemic descendants 
retain a primitive phenotype.  Signaling pathways and transcriptional regulators that govern the 
hierarchical production of blood cells may also be present in hematopoietic malignancies.  
Morever, the clinical importance of hematopoiesis is undeniable – benign hematopologic and 
bone marrow failure syndromes, leukemia, lymphoma, myeloma and myelodysplastic syndromes 
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all orginate from hematopoietic cells.  HSCs also serve as a source of marrow transplantations to 







CHAPTER 2: METHODS TO STUDY NORMAL AND MALIGNANT HEMATOPOIESIS 
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Identification of cell types  
By morphology 
Several techniques are available to distinguish the different types of blood cells according to their 
different biological and functional characteristics.  Firstly, different types of blood cells can be 
identified by their distinct morphology.  This is done by staining blood cells and bone marrow 
aspirates with the Wright-Giemsa stain, and examining them under a light microscope.  The 
hematoxylin eosin stain is also used on tissue sections such as the bone marrow and spleen to 
distinguish different cell types.  Other cytochemical stains that are more specific for certain cell 
types, such as the myeloperoxidase stain and the chloro-acetate esterase, are also routinely used in 
the diagnosis and classification of acute leukemias.4   
 
By cell surface markers 
Hematopoietic cells can also be identified and isolated based on the unique cell surface molecule 
expression on these cells, and has been greatly facilitated by technological advances in 
monoclonal antibody availability and flow cytometry.  HSCs can be readily identified by multi-
parameter flow cytometry analysis.  Although different groups have developed different antibody 
combination schemes to purify HSCs from mouse bone marrow, they are all driven by the same 
goal of isolating the highest yield of long-term, self-renewing, multi-lineage reconstituting HSCs.  
Almost all of these strategies revolve around the positive selection for the markers cKit and Sca1, 
and negative selection for markers of mature hematopoietic cell lineages (typically B220, CD4, 
CD8, Gr1, Mac1 and Ter119).  This cKit+ Lin- Sca1+ (KSL) phenotype greatly enriches for the 
ability of these cells to reconstitute hematopoietic activity, but also contains progenitor cells in 
addition to long-term HSCs.  Other strategies to identify HSCs include CD34 and FLT3 with 
KSL, CD150 and CD48 with or without KSL, as well as the Hoechst-effluxing side population 
(SP).5-7 The analysis of short-term HSCs and hematopoietic progenitor cells include phenotypes 
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to identify common lymphoid progenitors (CLP) and common myeloid progenitors (CMP), as 
well as their downstream progeny including pro-T and pro-B cells in the lymphoid lineage and 
megakaryocyte-erythrocyte progenitors (MEP) and granulocyte-macrophage progenitors (GMPs) 
in the myeloid lineage.  CLPs can be identified in whole bone marrow using KSL with IL7α.  The 
CMP population is identified in the Sca-negative portion of the KSL compartment, and is also 
negative for IL7α.  This fraction can be further subdivided into CMP (CD34+ CD16/32-), MEP 
(CD34- CD16/32-) and GMP (CD34+ CD16/32+).  Furthermore, these different hematopoietic 
stem and progenitor cell populations can be purified by cell sorting.7  Mature blood cells can also 
be identified by their cell surface phenotype in peripheral blood.  B220 identifies the B-
lymphocytes, CD3 and CD4 identify the T-lymphocytes, and Mac1 and Gr1 identify the myeloid 
cell lineage in peripheral blood.   Healthy blood should contain all the mature B, T-cell and 
myeloid lineages in order to carry out its normal functions.   
 
By function 
Hematopoietic stem and progenitor cells can also be identified according to their function.  HSC 
function is generally monitored according to their functional contribution to generating blood 
cells.  The best method to do this in vivo is to transplant test cells into recipient animals in which 
their hematopoietic system has been ablated by radiation.  The function of the transplanted bone 
marrow cells are then assessed by determining the level of chimerism of the recipients by 
sampling their peripheral blood samples at various timepoints after the transplant.  The recipient 
and donor mice have different alleles of the CD45 antigen (donor cells are typically isolated from 
CD45.2 mice with the standard C57BL/6 allele, while recipient mice are usually the CD45.1 
congenic strain), which can be distinguished using specific monoclonal antibodies against 
CD45.1 and CD45.2.  The function of transplanted HSCs can be assessed in terms of overall 
contribution to the recipient’s peripheral blood chimerism by engraftment of donor cells, as well 
as the types of hematopoietic cells generated from the transplanted HSCs by lineage analysis of 
 8 
peripheral blood.  Antibodies are used to track the three main mature blood lineages in peripheral 
blood - myeloid cells (Gr-1+, Mac-1+), B cells (B220+) and T cells (CD4+, CD8+).  By 
comparing the distribution of cell types formed from transplanted test cells to wild-type controls, 
we can determine if the transplanted cells have functional bias for making particular lineages.  
Timing of hematopoietic constitution can also be used to determine function of hematopoietic 
stem and progenitor cells.  After 4-weeks, the peripheral blood cells formed from input test cells 
can be the progeny of short-term HSCs or long-lived progenitors.  However, the only test cells 
that can self-renew for 16-weeks post-transplant are long-term HSCs; thus, the peripheral blood 
components generated from test cells after this time period are the progeny of these cells.  The 
myeloid progenitor function of bone marrow cells can also be functionally assessed in vitro by 
plating these cells in semi-solid media supplemented with cytokines to promote the growth of 
these myeloid progenitor colonies.  Colonies can be scored according to their distinct 
morphology.  
 
Mouse models of hematopoiesis and leukemia  
The mouse has been used extensively to study hematopoiesis and model human hematologic 
malignancies to investigate the basic genetic and biochemical components of malignant behavior.  
Furthermore, mice can also be used in the preclinical evaluation of novel therapies.8 Controlled 
experiments that are difficult or impossible in humans can be performed in mice, and unlike 
patients, mice can be designed to have both a defined genotype and congenic siblings that serve 
as controls.   
 
Several distinct methods can be used to introduce oncogenic mutations into the murine 
hematopoietic system.  In conventional transgenic models, an oncogene is integrated at a random 
site in the genome.  Retroviral transduction is a rapid method for generating series of genetically 
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related leukemias.  In some cases, proviral insertion can be deliberately exploited to generate 
leukemias by insertion mutagenesis.9 While these systems have proven quite valuable, they suffer 
from poor control over oncogene copy number and expression pattern due to integration effects.  
Conditional gene targeting addresses these concerns by modifying the endogenous locus of a 
proto-oncogene or tumor suppressor gene and allows a mutation be induced at a specific time 
and/or lineage.  To date, this approach provides the most accurate genetic model of oncogenic 
mutations.  Xenograft models where human leukemia cells are engrafted into 
immunocompromised mice have also been generated.  Although this system lacks the ability to 
be genetically manipulated, the main advantage is that actual human leukemia cells are used.   
 
Limitations and advantages 
Although mouse models have become an indispensable tool in hematopoiesis and cancer 
research, they have to be used with discretion.   Firstly, the genetically engineered oncogene may 
not fully recapitulate what is actually happening in the patient, and may not represent initiating 
events in human hematologic cancers.  Secondly, differences in pharmacology and toxicity in the 
mouse may also be challenging in translating preclinical drug studies into patients.  Nonetheless, 
there are extensive similarities between human and mouse hematopoiesis.  There is also an 
amalgam of techniques to assess cell biology in both normal and diseased states of hematopoiesis 
in the mouse.  Generous amounts of hematopoietic cells can be easily obtained from the tissues 
such as the bone marrow, spleen and peripheral blood, and characterized.  Hematopoietic 
malignancies can often times be transplanted into naïve hosts to propagate the disease in these 
recipients.  This not only allows the system and diseased organisms to be scaled up, it also allows 
for the study of the self-renewal function of diseased donor cells.  Mouse bone marrow 
transplantation has been the gold standard for the functional characterization of HSC activity.  It 






CHAPTER 3: PERTURBATIONS TO NORMAL HEMATOPOIESIS USING LOW 
DOSE-RATE RADIATION, EFFECT OF CHLOROQUINE1 
                                                 
1 Reprinted from Int J Radiat Oncol Biol Phys, Vol 84(3), Lim Y, Hedayati M, Merchant AA, Zhang Y, Yu HH, Kastan 
MB, Matsui W, Deweese TL., Chloroquine improves survival and hematopoietic recovery after lethal low-dose-rate 




The biologic effects of ionizing radiation have been studied for over a century, but it was not until 
the deployment of the atomic bomb in 1945 that the clinical manifestations of total body 
irradiation (TBI) were fully realized.  Following acute radiation exposure, hematopoietic defects 
in particular are observed and are an important cause of death.  This phenomenon has been 
attributed to the depletion of rapidly cycling and highly sensitive hematopoietic progenitors 
leading to myelosuppression.10-13 Radioprotective agents that allow survival of these short-lived 
myeloerythroid progenitor cells to replenish mature blood cells may prevent mortality from 
radiation-induced hematopoietic injury.   
 
Radiation dose-rate is an important factor determining the extent of cellular toxicity during 
radiation exposure.14 Previous studies have found that the delivery of radiation doses at low dose-
rates (LDR) may result in greater or lesser amounts of cell killing in vitro compared to equivalent 
doses delivered at higher dose-rates.15, 16 At specific dose rates (> 5 cGy/hr), greater cell survival 
is observed compared to equivalent doses applied at higher dose rates, presumably because of on-
going repair of radiation-induced injury during the protracted exposure.  This has been termed the 
“low dose rate effect”.17, 18 In contrast, dose rates of < 2cGy – 1Gy/hr can actually increase cell 
death relative to the same total dose delivered in a rapid, acute fashion and has been termed the 
“inverse dose rate effect”.15, 19-21 This has been hypothesized to be a result of alterations in cell 
cycle or reduced repair of radiation-induced DNA injury.21, 22 One of the key proteins involved in 
the response of mammalian cells to radiation-induced injury is ataxia telegectasia mutated (ATM) 
that is activated by autophosphorylation following DNA damage.23 Once activated, ATM 
subsequently phosphorylates other key proteins involved in the repair of DNA damage.24 The 
anti-malarial agent, chloroquine, has been shown to activate ATM without inducing DNA injury 
presumably by altering chromatin structure.23, 25 Intriguingly, ATM is not activated by LDR 
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radiation, but the addition of chloroquine to cancer cells growing in vitro prior to LDR radiation 
exposure activates ATM and subsequently reduces cell death from LDR.26 We examined whether 
chloroquine could similarly act as a radioprotective agent in vivo and treated mice with 
chloroquine prior to LDR radiation exposure.  We found that chloroquine improved survival of 
the animals by enhancing the recovery of hematopoietic progenitors responsible for early 
engraftment.  Furthermore, the effects of chloroquine were dependent on the activation of ATM 
protein.  These data serve to expand knowledge regarding the role of ATM in radiation injury in 
mammals and highlight the possibility that drugs like chloroquine may serve as modulators of 





Cell proliferation assay 
Human fibroblast cells obtained from an ATM-/- patient were immortalized using hTERT 
(GM05823-hTERT ATM-/-).  Immortalized wild-type human fibroblast cells (HFF-hTERT 
ATM+/+) were used as control.  Cells were cultured in DMEM with 10% FBS and treated with 
48μg/ml chloroquine for 4h, then washed with PBS and cultured in 10 ml of fresh medium.  
Flasks were gassed with 5% CO2, sealed and kept in the low dose-rate irradiator for 42.5hrs at 
37°C for a total radiation exposure of 4 Gy at a rate of 9.4 cGy/hr.  Cell proliferation was 
assessed using Cell titer Blue (Promega, Madison, WI).  Fluorescence was measured using a 
microplate system (SpectraMax M2, Molecular devices).  1000 cells/well were used for GM5823-
hTERT (ATM-/-) and 400 cells/well were used for HFF-hTERT (ATM+/+).    
 
Mice 
Male C57BL/6-CD45.2 mice (Harlan Laboratories, Indianapolis, IN) were used as bone marrow 
donors and female C57BL/6-CD45.1 mice (National Cancer Institute) as transplant recipients.  
Male C57BL/6 Atm null mice were used in experiments to determine the influence of ATM in 
total body radiation-induced death (St. Jude Children’s Research Hospital, Memphis, TN).27 Atm 
status was confirmed by PCR of mouse genomic DNA.  All the mice were used at 4 weeks of 
age, and housed under specific pathogen-free conditions in an accredited facility at the Johns 
Hopkins Medical Institutions.  All experiments were conducted using protocols approved by the 




Radiation exposure and chloroquine administration  
Wild type C57BL/6 donor mice were exposed to 12.8 Gy of TBI in a custom-built low dose-rate 
irradiator at 9.4 cGy/hr for 5.5 days (total of 136 hrs).16 Atm-/- mice were similarly treated but 
received a total of 9 Gy, given their greater radiosensitivity.27 Bone marrow recipient mice were 
conditioned with 10 Gy given as two 5 Gy fractions 4hrs apart prior to bone marrow 
transplantation.  Chloroquine (Sigma-Aldrich, St. Louis, MO) was dissolved in PBS, filter-
sterilized and injected intraperitoneally (0.0594 mg per 17g body weight) in two doses 
administered 24hrs and 4hrs prior to LDR radiation exposure.  
 
Bone marrow transplantation 
Donor mice were sacrificed by cervical dislocation immediately after LDR radiation exposure.  
Bone marrow cell suspensions were prepared by crushing the tibia, fibula and vertebral bones 
with a mortar and pestle in sterile PBS followed by passage through a 70-μm filter.  Bone marrow 
cellularity was determined using a Coulter counter.  Whole bone marrow cell suspensions in PBS 
(300 μl total volume) were injected via the retro-orbital venous sinus into lethally irradiated 
recipients.  
 
Complete peripheral blood cell count 
Peripheral blood (50 μl) was collected from murine retroocular vessels using heparinized 
capillary tubes and complete blood cell counts were obtained using a Hemavet950 Hematology 
system (Drew Scientific, Oxford, CT).   
 
In vitro methycellulose colony forming assay 
Whole bone marrow cell suspensions were cultured in semi-solid methylcellulose medium 
(M3434, Stem Cell Technologies, Vancouver, Canada) supplemented with recombinant murine 
SCF (50 ng/mL), IL-3 (10 ng/mL), IL-6 (10 ng/mL), GM-CSF (10 ng/mL) and EPO (3 U/mL).  
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Cells were incubated at 370C with 5% CO2, and total number of colonies were counted after 10 
days using an inverted microscope.  
 
In vivo progenitor assay 
1 X 107 whole bone marrow cells were harvested from LDR radiated mice, mixed with 2 X 105 
congenic CD45.1 un-irradiated bone marrow cells and transplanted into lethally irradiated 
C57BL/6 CD45.1 recipients.  To assess donor engraftment, peripheral blood (50 μl) was drawn 
via retro-orbital bleeding into heparinized capillary tubes and stained with anti-mouse CD45.1-
FITC and CD45.2-PE antibodies (eBioscience, San Diego, CA), followed by flow cytometry.  
 
Lineage depletion and FACS analysis 
Whole bone marrow cell suspensions were stained with a mixture of purified biotin conjugated 
monoclonal antibodies recognizing mouse Ter-119, CD3e, B220 and Gr-1 (eBioscience, San 
Diego, CA).   Cells positive for lineage markers were partially removed by magnetic bead 
depletion on a LD column with Anti-Biotin MicroBeads, mouse IgG1 isotype (Miltenyi Biotech, 
Auburn, CA).  The remaining lineage depleted cells were collected in the flow through from the 
magnetic columns and treated with 35 μg/mL of chloroquine (Sigma) for 2.5hrs at 37°C and 5% 
CO2.  To detect phosphor-ATM expression, the lineage depleted cells were washed with PBS, 
fixed in 2% formaldehyde for 10 minutes at room temperature, permeabilized with a mixture of 
cold 50% methanol and 50% acetone and blocked with 2% FBS in PBS overnight.  Cells were 
then stained with anti-pATM-PE (clone 10H11.E12, Millipore, Billerica, MA), which recognizes 
phosphorylated Ser-1981, and analyzed using a FACSCalibur flow cytometer (Becton Dickinson, 






Whole bone marrow cells from chloroquine treated or untreated mice were analyzed by western 
blot according to standard protocols. Briefly total cell lysates were prepared from about 5 x 107 
whole bone marrow cells. About 200 μg of the total cell lysate was loaded per lane. Total p53 
was detected by using anti p53 (EMD Chemicals, Gibbstown, NJ) and phosphorylated p53 was 
detected by using anti mouse phospho-p53 (S18) antibody (R&D SYSTEM, Minneapolis, MN) at 
final concentration of 2 μg/ml. 
 
Statistical analysis 
Survival was calculated using Kaplan Meier analysis and a log rank test.  Results are presented as 
the mean ± standard error of the mean.  Comparisons between 2 groups, chloroquine treated and 
untreated, were performed using a 2-tailed, un-paired Student t-test. P values <0.05 were 




ATM is necessary for the radioprotective effect of chloroquine 
Chloroquine has long been utilized as an anti-malarial agent.  It is also known to induce the 
activation of ATM and has been shown to abrogate the enhanced cytotoxicity of LDR radiation in 
vitro.26 To further examine whether the radioprotective effect of chloroquine is dependent on 
ATM, we analyzed the effect of chloroquine on hTERT immortalized human fibroblasts derived 
from normal donors or patients with ataxia-telangiectasia that lack ATM activity.  Treatment of 
normal fibroblasts with chloroquine prior to LDR radiation improved cell viability, similar to our 
previous in vitro findings using cancer cells (Figure 3.1A).15 In contrast, chloroquine failed to 
protect ATM deficient fibroblasts from LDR irradiation (Figure 3.1B).  Compared to untreated 
animals, mice pre-treated with two doses of chloroquine demonstrated significantly improved 
survival rates (Figure 3.1C, 21% vs. 79%; P<0.05).  We also examined whether ATM was 
specifically required for chloroquine-mediated protection from LDR radiation in vivo and treated 
Atm null transgenic mice with or without chloroquine prior to LDR radiation exposure.  In 
contrast to wild-type mice (Figure 3.1C), we detected no significant differences in survival 
between chloroquine treated and untreated Atm null mice (Figure 1D, 61.5% vs. 69.2% P= 0.86).  









Figure 3.1: Radioprotection by chloroquine requires ATM in vitro and in vivo.  
(A) Effect of chloroquine on the proliferation of wild type ATM+/+ human fibroblast cell line 
(HFF-hTERT) in the presence of ATM following 4Gy of ionizing radiation at LDR radiation 
exposure.   
(B) Effect of chloroquine treatment on ATM deficient fibroblast cells (GM5823 hTERT).   
(C) Kaplan-Meier survival analysis of wild-type C57BL/6 mice exposed to LDR radiation.  Mice 
were untreated (dashed line, n=29), or pre-treated with chloroquine before LDR radiation 
exposure (solid line, n=24; *P< .05)  
(D) Kaplan-Meier survival analysis of Atm-/- mice treated with or without chloroquine prior to 






Low dose-rate radiation induces lethal bone marrow failure 
The ability of bone marrow transplantation to rescue acutely irradiated mice indicates that death 
results from hematopoietic failure.28 Since radiation exposure over a protracted time period can 
enhance cell death in vitro, we examined whether bone marrow failure was similarly responsible 
for death following lethal irradiation delivered at a low dose-rate.  We initially exposed C57BL/6 
mice to 12.8 Gy of TBI at a rate of 9.4 cGy/hr for 136 hours and found that only 6 of 29 (21%) of 
animals survived by day 35.  However, all mice (n=10) receiving whole bone marrow (1 X 106 
cells) immediately after LDR radiation survived for greater than 35 days (Figure 3.2, P<0.05).  
Full necropsies following treatment with LDR radiation alone failed to demonstrate significant 
damage to the lungs or gastrointestinal tract (data not shown), suggesting that impaired 
hematopoiesis is a primary cause of death following exposure to LDR radiation in these animals.   
 
Figure 3.2: LDR radiation causes bone marrow failure 
Kaplan-Meier survival analysis of wild-type C57BL/6 mice exposed to LDR radiation.  Mice 
were untreated (dashed line, n=29), or transplanted with 1x 106 whole bone marrow cells (solid 





Chloroquine protects hematopoietic progenitors from LDR radiation 
Bone marrow rescue following acute lethal radiation is primarily mediated by committed myeloid 
progenitors.29 We examined the effects of chloroquine treatment on myeloid progenitor cell 
function by plating whole bone marrow cells from LDR irradiated mice in methylcellulose and 
quantifying colony-formation.  LDR radiation alone decreased the total number of bone marrow 
cells by 5-fold (data not shown) and colony formation compared to un-irradiated samples (Figure 
3.3A, 0.76 vs. 13).  However, compared to untreated animals, chloroquine treatment significantly 
improved the recovery of total myeloid colony forming unit (CFC) following radiation (Figure 
3.3A, 0.76 vs. 1.57; P< .05).  Furthermore, this effect was primarily due to protection from 
radiation injury as no significant differences in myeloid CFC were observed in un-irradiated mice 
treated with or without chloroquine (Figure 3.3A; P=0.30).    
 
We also examined the effects of chloroquine on the in vivo recovery of myeloid progenitors and 
transplanted 1 X 107 whole bone marrow cells from LDR irradiated C56BL/6 CD45.2 donor mice 
into congenic C57BL/6 CD45.1 recipient mice.  Since myeloid progenitors are responsible for 
early engraftment, we quantified the peripheral blood chimerism by flow cytometry starting 2 
weeks following bone marrow transplantation.  In mice receiving bone marrow from LDR 
irradiated mice pretreated with chloroquine, the frequency of peripheral blood CD45.2 donor cells 
was significantly increased compared to untreated mice by 6 weeks post transplant (Figure 3.3B, 
4.33% vs. 1.00%; P=0.015).  In comparison, chloroquine treatment did not impact long-term 
engraftment (> 12 weeks) of LDR radiated bone marrow (data not shown), suggesting little 
impact on long-term hematopoietic stem cells.  Therefore, the enhanced survival of LDR 




Figure 3.3: Chloroquine protects hematopoietic progenitors from LDR radiation in vitro 
and in vivo.   
(A) Hematopoietic progenitor colony formation in vitro.  Chloroquine pre-treated or untreated 
whole bone marrow cells from LDR irradiated or non-irradiated mice were assessed for colony 
formation after 10 days in methylcellulose (P<0.05; n=3).  
(B) In vivo engraftment analysis of mice transplanted with 1x 107 whole bone marrow cells 
following LDR irradiated with or without chloroquine treatment.  Peripheral blood was stained 
with CD45.1 and CD45.2 antibodies to assess chimerism.  Each data point is representative of 







Chloroquine activates ATM in mouse hematopoietic progenitor cells 
Chloroquine binds to DNA by intercalating between bases and alters the internucleosomal DNA 
helical twist and chromatin structure in vitro and in vivo.30, 31 Changes in chromatin structure 
subsequently induce the activation of ATM, a key mediator of the DNA damage response.23 
Chloroquine has also been shown to activate ATM and its downstream effectors in vivo.32 
Therefore, chloroquine is thought to protect cells from LDR radiation by activating ATM and 
subsequent downstream effectors.  Since chloroquine improved the recovery of myeloid 
progenitors following lethal LDR radiation, we examined whether it activated ATM in these 
cells.  We isolated lineage-depleted mouse bone marrow cells and treated them with chloroquine 
(35 µg/ml for 2 hours) and examined the activation status of ATM by flow cytometry.  Compared 
to untreated cells, chloroquine significantly increased the expression of activated phosphorylated 
ATM by approximately 2.5 fold (Figures 3.4A and 3.4B; P< .05). We also examined the 
expression of phosphorylated ATM following in vivo treatment with chloroquine; however, we 
did not detect significant ATM activation in lineage negative bone marrow cells likely due to the 
cellular processing required to isolate hematopoietic progenitors.  We could not detect 
phosphorylated ATM by standard western blotting techniques of whole bone marrow obtained 
from treated mice.  The difficulty of detecting phosphorylated ATM in mouse tissue has been 
reported.32 Previous studies have used the activation status of p53, a downstream target of 
activated ATM, as a surrogate for in vivo ATM phosphorylation and have shown increased p53 
phosphorylation in tissues from chloroquine treated mice.32 Therefore, we examined the level and 
activation status of p53 in bone marrow cells obtained from mice treated with chloroquine. 
Chloroquine treatment increased the levels of both total and phosphorylated p53 (Ser 18) as 
detected via western blot analysis, consistent with canonical ATM activation (Figure 3.4C).  
Taken together these results support in vivo activation of ATM in bone marrow cells by 
chloroquine. 
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Figure 3.4: Chloroquine activates ATM in mouse hematopoietic progenitor cells.     
(A) Lineage depleted mouse bone marrow cells were treated with chloroquine and analyzed by 
flow cytometry for pATM expression.  Quantitation of phosphorylated ATM expression by flow 
cytometry analysis (P<0.05; n=3).   
(B) Representative dot plots gated on forward and side scatter followed by pATM expression.  
Untreated cells were stained as a control.   
(C) Western blot of p53 expression in mouse bone marrow cells used as surrogate for ATM 
activation. Radiation treated mouse used as positive control for p53 phosphorylation received 5 
Gy of acute TBI. Graph of quantitative fold change of total p53 and p53-p normalized to beta-










Protracted LDR radiation exposures arising from nuclear accidents and terrorism events may pose 
serious threats to public health.  While it is well known that deaths from hematopoietic defects 
occur following acute radiation exposure, we found that bone marrow transplantation can 
similarly rescue mice following LDR radiation.  Therefore, bone marrow failure is a primary 
cause of death, and chloroquine can protect myeloid progenitors from LDR radiation resuting in 
improved overall survival.  
 
Despite the potentially devastating consequences of LDR radiation exposure, few protective 
agents are currently available.33 Agents that confer radioprotection can be generally classified into 
three categories:  sulfhydryl compounds, antioxidants and receptor-mediated agents such as 
lipids, cytokines and growth factors.34 Cysteine, a sulfur containing amino acid, was first shown 
to protect rats from lethal x-radiation.35 Similarly, nutraceuticals, such as N-acetyl cysteine or 
genistein, have been found to provide a hematopoietic radioprotective effect in animal models by 
protecting cells from oxidative stress.36 Hematopoietic growth factors and cytokines have also 
been shown to improve animal survival after TBI.37 These agents have been proposed as 
protective agents following radiation exposure during cancer therapy and or in the event of a 
nuclear accident.  However, many of these agents lack the properties of robust activity, prolonged 
efficacy, broad specificity and minimal toxicity required to effectively protect a large population 
during a radiological emergency.  There is great potential for chloroquine to serve as a potential 
radioprotective agent following LDR radiation exposure since it is a cheap, widely available drug 
with minimal side effects.   
 
The precise molecular mechanisms by which chloroquine protects cells from LDR radiation are 
unknown, but some radioprotective agents, such as aminothiol compounds, are thought to 
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structurally stabilize DNA and decrease the rate of DNA replication.38 Similar to aminothiols, 
chloroquine binds to DNA and its intercalation between DNA bases results in the structural 
modification of chromatin.39 This alteration in chromatin structure has been associated with the 
activation of ATM in cell lines.23 Likewise, we found that chloroquine activates ATM in 
hematopoietic progenitors, and several potential mechanisms may confer radioresistance.  The 
well-recognized role of ATM in regulating the DNA damage response suggests that it may 
activate DNA repair pathways that otherwise fail to be induced by LDR radiation.40 ATM also 
regulates the cellular response to oxidative stress and reactive oxygen species (ROS) that are 
increased following radiation exposure.41 In the hematopoietic system, the loss of ATM results in 
impaired hematopoietic stem cell function that is associated with increased levels of ROS.42, 43 
Although we did not observe differences in the long-term engraftment of bone marrow derived 
from chloroquine treated animals indicative of effects on hematopoietic stem cells, it is possible 
that ATM activation enhances cytoprotective mechanisms within progenitors that abrogate the 
damaging effects of increased levels of ROS following exposure to LDR radiation.44 Recently, 
ATM has also been found to play a role in regulating cellular metabolism and autophagy in 
response to increased ROS levels by activating TSC2 and the LKB1/AMPK pathway to 
ultimately repress mTORC1 signaling.45-47 Several studies have demonstrated that the loss of 
Lkb1 severely impairs hematopoiesis in mice primarily by decreasing mitochondrial function.48-50 
Therefore, it is also possible that chloroquine-induced activation of ATM and subsequent 
LKB1/AMPK signaling may improve the survival of hematopoietic progenitors through the 
expression of anti-apoptotic factors or modulating autophagy or energy metabolism.  
 
Oxidative stress is an important consequence of chronic radiation exposure and affects a myriad 
of organ systems.  The consequences of protracted radiation exposure and oxidative stress are 
often difficult to study because the detrimental effects of extended radiation exposure shorten the 
lifespan of cells and animals.  We have shown that chloroquine or bone marrow transplantation 
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can prolong the life span of mice exposed to lethal LDR radiation.  Therefore, this model may 
also be useful in studying the effects of prolonged radiation and oxidative stress on degenerative 










Hedgehog signaling cascade2               
  
The Hedgehog (Hh) signaling pathway was first identified in Drosophila almost 30 years ago as 
genetic loci required for proper anterior-posterior segmental patterning.52 By examining 
mutations that disrupt the Drosophila larval body plan, Nusslein-Volhard and Weischaus 
identified several genes that resulted in the duplication of denticles, the spiked cuticular processes 
located on the anterior half of each body segment, as well as the loss of naked cuticles on the 
posterior segment.  The appearance of a continuous lawn of denticles was reminiscent of the 
spines of a hedgehog and gave rise to the characteristic name of the soluble factor and signaling 
pathway responsible for this phenotype.  The disruption of antero-posterior positional information 
within the thoracic and abdominal segments suggested that Hh acts in a wide variety of 
developmental processes and serves as a classical morphogen to specify cell fates during 
embryogenesis.   Subsequent cloning and study of the Hh gene identified it as a unique secreted 
signaling factor that regulates cell proliferation, migration and differentiation during tissue and 
organ formation.53 As exemplified by Drosophila wing development,54 Hh-mediated 
morphogenesis occurs in a spatial, temporal and dose-dependent fashion.  Here, Hh ligand is 
expressed and secreted by cells within the posterior compartment of the imaginal disc to establish 
a spatially defined concentration gradient across the anterior segment.  Anterior segment cells 
respond to the local concentration of Hh ligand by modulating the expression of target genes and 
differentiating into distinct cell types to produce the mature wing.55  Hh signaling is widely active 
during Drosophila development, and it is also required for proper formation of the leg and eye.56, 
57 Detailed studies in mice have demonstrated that the Hh pathway is highly conserved as it is 
required for the development of many organs, especially the skeletal and central nervous 
                                                 
2 Reprinted from Crit Rev Eukaryot Gene Expr, Vol 20(2), Lim Y, Matsui W, 129-139, Copyright (2010), with 
permission from Begell House 
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systems.58 Moreover, in some post-natal organs, the Hh pathway plays an important role in 
maintaining tissue homeostasis as well as repair and regeneration following injury.59  
In Drosophila, the Hh ligand is initially synthesized as a 45 kDa precursor that undergoes several 
post-translational modifications to form the active signaling molecule.60, 61 A 19 kDa amino-
terminal fragment is initially produced by an intramolecular cleavage reaction catalyzed by the 
carboxy-terminal portion of the precursor.  It is then covalently coupled to two lipid molecules, 
cholesterol and palmitic acid, that further enhance its biologic activity and limit its diffusion 
within the extracellular space.62, 63 These modifications are conserved within all Hh ligands from 
Drosophila to humans.64 Cells responding to Hh ligand require two essential proteins, Patched 
(Ptch), a 12-pass transmembrane protein that serves as the Hh ligand receptor,65 and Smoothened 
(Smo), a 7-pass transmembrane signal transducer.66 Unlike many cellular pathways in which 
receptors function as signal transducers and directly induce pathway activity following ligand 
binding, Ptch represses Smo and inhibits pathway signaling in the absence of Hh ligand.67 Upon 
ligand binding, the inhibitory effect of Ptch on Smo is relieved and signaling is activated.  The 
nature of the interaction between Ptch and Smo remains poorly understood, but studies have 
suggested that they do not physically interact within the plasma membrane.  Instead, Ptch is 
thought to catalytically regulate Smo by modulating the production or transport of a small 
molecule, and recent studies in vertebrates have suggested that oxysterols, including vitamin D3, 
may serve as this intermediary.68-70 Smo activation ultimately results in activation of Cubitus 
interruptus (Ci), a zinc finger transcription factor that acts as either an activator or repressor of 
gene expression depending on its post-translational processing.71 Cytoplasmic Ci is normally 
bound to the kinesin-like protein Costal2 (Cos2) allowing interaction with a number of other 
cellular factors including the serine/threonine protein kinase Fused (Fu), Suppressor of Fused 
(SuFu), Protein Kinase A, Glycogen Synthase Kinase 3, and Casein Kinase 1.72, 73 In the absence 
of Hh ligand, full-length Ci is phosphorylated and undergoes limited proteolysis that removes the 
N-terminal transcriptional activation domain.74 As a result, truncated Ci enters the nucleus and 
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acts as a transcriptional repressor.  Following the activation of Smo, Ci phosphorylation is altered 
and full-length Ci induces the expression of Hh target genes.  The interpretation of different local 
concentrations of Hh ligand and specification of Ci transcriptional activity are beginning to be 
understood.  Intermediate levels of Hh ligand result in the binding of Ci to SuFu in the cytoplasm, 
restricting nuclear import.75 Stimulation by high levels of Hh ligand results in the 
dephosphorylation of Ci, allowing its dissociation from SuFu, and entry into the nucleus. 
 
Divergence in Hedgehog signaling 
Despite the functional conservation of the Hh pathway and many of its components, several 
differences still exist between Drosophila and vertebrates.  While only one Hh gene exists in 
Drosophila, three ligands have been identified in vertebrates, Sonic hedgehog (Shh), Indian 
hedgehog (Ihh) and Desert hedgehog (Dhh).53, 76 Dhh is most closely related to Drosophila Hh, 
while Ihh and Shh are more related to one another.  Shh is widely expressed in vertebrates 
including three key signaling centers within the embryo, the notochord, the floor plate, and the 
zone of polarizing activity.77 Hence Shh deficiency is embryonically lethal due to multiple defects 
in early to mid gestation.53  Ihh is found within hematopoietic cells, bone, cartilage, and the eye, 
whereas Dhh is primarily expressed in the gonads, external genitalia, eyes and peripheral nerves.  
The activity of the single Ci transcription factor in Drosophila has been expanded to include three 
homologues, Gli1-3, in mammals.78, 79 Gli1 serves as a positive effector of Hh signaling, whereas 
Gli3 acts as a transcriptional repressor.  Gli2 can function as both a positive and negative 
transcriptional regulator that is specified by both post-transcriptional and post-translational 
modifications.80 The overall output of transcriptional activity is dictated by the balance between 
activator and repressor forms of these three transcription factors.81  
 
Cellular localization of Hh pathway components 
The cellular localization of pathway components also plays an important role in Hh pathway 
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activation.  In Drosophila, Smo is localized within intracellular vesicles in the absence of ligand, 
then translocated to the plasma membrane upon ligand binding.82 In vertebrates, the localization 
of pathway components occurs within the context of primary cilia.83 In the absence of ligand, 
Ptch is located within the primary cilia whereas Smo is diffusely found within the plasma 
membrane.84 Following ligand binding, Ptch moves out the primary cilia and Smo moves into the 
cilia where it interacts with Glis that subsequently enter the nucleus.85, 86  
 
Abnormalities from aberrant Hh signaling 
Given the conserved role of the Hh signaling pathway in development, it is not surprising that 
defects in pathway activity lead to congenital abnormalities in humans.58, 87 Holoprosencephaly 
(HPE) is a cephalic disorder of varying severity characterized by the incomplete cleavage of the 
forebrain during embryogenesis.88 The precise causes of HPE are unknown, but SHH 
haplosufficiency is clearly associated with this disorder in humans.  In mice, the loss of a single 
copy of the Shh gene does not lead to HPE, but deletion of both alleles results in cyclopia and 
fusion of the cerebral hemispheres suggesting that forebrain development in humans is more 
sensitive to SHH loss than mice.89 Mutations in Ihh result in brachydactyly that is characterized 
by shortened phalanges or metacarpals.90, 91 GLI3 mutations have been identified in several 
congenital malformation syndromes that display characteristic limb abnormalities, including 
Greig Cephalopolysyndactyly and Pallister-Hall Syndrome.92, 93 Mutations that inactivate PTCH1 
are among the best-recognized congenital defects arising from mutations within the Hh signaling 
pathway.  Loss-of-function genetic lesions result in aberrant pathway activity and Gorlin 
Syndrome characterized by congenital defects of the brain and skeletal system.94 Patients with 
Gorlin Syndrome are also predisposed to develop advanced basal cell carcinomas of the skin, 
medulloblastomas, and rhabdomyosarcomas suggesting that Ptch1 functions as a tumor 
suppressor.95-97 This was the first evidence of aberrant Hh signaling in causing cancers in Gorlin 
syndrome patients.  Interest in the Hh pathway subsequently strengthened by increasing evidence 
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that the abnormal regulation of the Hh pathway has been widely implicated in tumorigenesis in a 
variety of organs and tissue systems.58, 98 Mutations in regulatory components of the pathway 
leading to constitutive activation of Hh signaling has also been identified in basal cell carcinoma 
(BCC) and medulloblastoma (MB).99-103   
 
Hedgehog signaling in hematologic malignancies 
In hematologic malignancies, several pre-clinical studies have implicated that Hh signaling may 
be important in the genesis, relapse and maintenance of these hematologic conditions, and have 
reinforced interest in using Hh inhibitors in these diseases.  In particular, Hh signaling has been 
shown to play a crucial role in maintaining leukemic stem cells in chronic myeloid leukemia 
(CML), and the effects of Smo deletion in CML have been explored using mouse models.   Zhao 
et al used the Vav-Cre-Lox system to isolate Smo deficient HSCs from Smo deficient mice, 
whereas Dierks et al used fetal liver cells from Smo deficient mouse embryos.104, 105 Both groups 
virally expressed BCR-ABL in these cells before transplanting them into recipient mice.  They 
found that Smo deletion reduced leukemic stem cell numbers and decrease the incidence of 
leukemia.  Pharmacologic inhibition also decreased leukemic growth in diseased mice.  They 
showed that Hh signaling is critical to maintaining the leukemic stem cell population in CML, 
and can be therapeutically targeted in the treatment of CML.  Similarly, in multiple myeloma, the 
disease initiating cells express constituents of the Hh pathway, and Smo inhibitors had the ability 
to reduce the population of these cells.106 Additionally, in precursor B-cell acute lymphoid 
leukemia (B-ALL), Smo inhibition also reduced self-renewal both in vitro and in vivo.107  
Although Hh signaling plays a role in maintaining disease initiating cell self-renewal in these 
diseases, less is known about its role in acute myeloid leukemia (AML).  Studies have shown that 
Mx1Cre deleted Smo is dispensable in a MLL-AF9 induced AML mouse model as well as Notch 
dependent T-cell acute lymphoid leukemia (T-ALL) model, suggesting that targeting Hh 
signaling may not be sufficient in these acute leukemias.108, 109 In the AML model, there was no 
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difference in phenotype as assayed by in vitro serial plating assays, in vivo AML disease 
penetrance or latency compared to the control Smo+/+ cells, in contrast to the findings in CML 
models.  In the T-ALL model, there was no change in the kinetics of disease onset or secondary 
transplants by genetic deletion or pharmacological inhibition of Smo. Nevertheless, components 
of the Hh signaling pathway have been shown to be expressed in leukemia cell lines and patient 
samples.  Recently, a study using a Smo inhibitor manufactured by Pfizer showed that 
antagonizing Hh signaling reduces dormant leukemic stem cell activity in AML patients, 
suggesting that Hh inhibition may have some efficacy in leukemia.  Hh inhibition also enhanced 
tyrosine kinase inhibitor sensitivity, providing a strong rationale for combinatorial therapy in 
leukemia.  These studies suggest a role of Hh signaling in being part of a core machinery driving 
myeloid leukemic stem cell maintenance in both CML and AML.    
 
FLT3-ITD mutations in AML 
FMS-like tyrosine kinase 3 (FLT3) is a class III receptor tyrosine kinase that is expressed on early 
hematopoietic stem/progenitor cells, and is vital for the development of normal levels of mature 
myeloid and lymphoid cells.110  On binding with the FLT3 ligand (FL), FLT3 is activated, which 
involves receptor dimerization and kinase activity by activating multiple downstream signaling 
pathways, including Ras/MAP kinase, AKT and STAT5.111, 112 High coexpression of FLT3 with 
FL may lead to dysregulation of activity via autocrine or paracrine mechanisms that promote 
leukemogenesis, as observed in MLL-rearranged infant ALL.113, 114 FLT3 mutations represent one 
of the most common molecular perturbations in acute myeloid leukemia (AML), accounting for 
30–35% of de novo cases.115, 116 Mutations of FLT3 lead to constitutive kinase activation.  These 
mutations generally occur in the juxtamembrane (JM) domain or in the tyrosine kinase domain 
(TKD).  The JM mutations factor in approximately 23% of newly diagnosed cases of AML and 
occur as in-frame internal tandem duplications (ITDs) of varying length, resulting in duplication 
of a sequence ranging typically from 4–50 amino acids, often accompanied by a one or two 
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amino-acid insert.  The JM domain functions as an autoinhibitory mechanism to regulate FLT3 
kinase activity, and disruption by mutations destabilize its conformation, leading to constitutive 
signaling.117  Point mutations to the kinase domain occur lower in frequency.  A recent study also 
reported that these D835Y point mutations result in less aggressive disease compared to the ITD 
mutations in a knock-in mouse model.118 The presence of FLT3-ITD mutations confers a poor 
prognosis to patients with AML.119, 120 Hence there is great interest in developing FLT3 inhibitors 
as a form of treatment for AML, and also in better understanding disease transformation in FLT3-
ITD driven leukemia.   
 
Our hypothesis 
Incidentally, activating or inhibiting mutations in components of the Hh pathway have not been 
found in hematopoietic malignancies; current data suggests that in most hematopoietic 
neoplasms, Hh signaling does not play an independent role in tumor initiation, but instead 
contributes to tumor maintenance, growth, drug resistance and cancer stem cell survival.  Perhaps 
Hh inhibition may work better in advance or relapsed AML, or in AML driven by certain 
mutations, such as FLT3 mutations.  More studies in the mechanistic role of Hh signaling in 
AML will be crucial in improving the use of Hh inhibitors in this devastating disease.  We aim to 
study the role of Hh signaling in AML pathogenesis, and show evidence of an efficient use of 
Smo inhibition in combinatorial therapy.  We found evidence of increased Hh signaling in 
secondary human AML patient peripheral blast samples, as well as advanced CML compared to 
the initial stages of disease.  Thus, we hypothesize that the Hh pathway plays a role in 
accelerating disease progression.  To model chronic myeloid proliferation, we used the FLT3-
ITD; Mx1Cre mouse, where fatal myeloproliferative disease, initiated by an activating mutation 
of the FLT3 tyrosine kinase receptor, develops with a median time of 10 months.121 We bred 
these FLT3-ITD mice with mice harboring the SmoM2 allele, and conditionally activated both 
alleles in the hematopoietic system in adult mice by way of Mx1Cre to interrogate the role of Hh 
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signaling in accelerating leukemia progression.  We found that SmoM2; FLT3-ITD; Mx1Cre 
mice (referred to as SmoM2; FLT3-ITD) developed rapidly fatal acute myeloid leukemia with 
100% penetrance by 3 months.  The disease is characterized by elevated white blood cell counts, 
splenomagaly, increased Gr1+ cKit+ cells in the bone marrow, and Mac1+ Gr1+ cells in the 
peripheral blood.  We also found that the increased Hh signaling in these mice enhanced the 
proliferation of myeloid progenitors, thus contributing to disease progression.  Inhibiting both the 
Hh and FLT3 signaling pathways with specific inhibitors in FLT3-ITD AML cell lines decreased 
cell growth and clonogenicity, and caused cell cycle progression arrest.  Furthermore, combined 
treatment using both the Hh and FLT3 inhibitors in vivo significantly improved overall survival 
of diseased mice.  This model sheds light on the role of developmental signaling pathways in 
accelerating cancer progression, and also provides rationale for combinatorial therapy with both 







Human AML and normal bone marrow and peripheral blood samples were collected under an 
institutionally approved protocol with informed patient consent in accordance with the 
Declaration of Helsinki.  Samples were obtained prior to therapy and/or at relapse.  Mononuclear 
cells were isolated by Ficoll centrifugation and cryopreserved in liquid nitrogen until use.  Total 
RNA was extracted from mononuclear cells using RNeasy Plus kit (Qiagen), and used for cDNA 
synthesis for qRT-PCR analysis.      
 
Mice 
FLT3-ITD; Mx1Cre mice harboring a FLT3-ITD mutation knocked into the endogenous FLT3 
locus were previously described.121 These mice were bred with SmoM2 mice purchased from the 
Jackson Laboratories to generate mice with the FLT3-ITD, SmoM2 and Mx1Cre alleles.  Female 
congenic C57BL/6 CD45.1 recipient mice, 4 – 6 weeks old, were purchased from the National 
Cancer Institute (NCI).  All mice were housed in a pathogen-free animal facility at the Johns 
Hopkins University School of Medicine.  All animal procedures were approved by the 
Institutional Animal Care and Use Committee.  
  
Generation and analysis of diseased mice 
DNA was extracted from tail fragments obtained from mice upon weaning.  The genotypes of the 
transgenic mice were determined by performing PCR reactions on the extracted DNA using the 






SmoM2 5’- AAG TTC ATC TGC 
ACC ACCG -3’ 
5’- TCC TTG AAG AAG 
ATG GTG CG -3’ 
FLT3-ITD 5’- CTC TCG GGA ACT 
CCC ACT TA -3’ 
5’- TGC AGA TGA TCC 
AGG TGA CT -3’ 
Mx1Cre 5’- GCG GTC TGG CAG 
TAA AAA CTA TC -3’ 
5’- GTG AAA CAG CAT 
TGC TGT CAC TT -3’ 
 
Mice harboring alleles heterozygous for both SmoM2 and FLT3-ITD were obtained.  All mice 
used in the study also had the Mx1Cre allele.  Littermates with just one copy of the SmoM2 or 
FLT3-ITD alleles were used as controls.  Wild type controls had the Mx1Cre allele only.  Upon 
weaning and genotyping, the mice were then administered with 5 doses of 300ug poly(I:C) via 
intraperitoneal injections every other day.  4 weeks after the last poly(I:C) injection, peripheral 
blood was obtained by retro-orbital bleeding using heparinized microcapillary tubes (Fisher).  
Complete blood count analysis was obtained using the Hemavet 950 Hematology Analyzer (Drew 
Scientific).  Peripheral blood was then lysed with red blood cell (RBC) lysis buffer, and DNA 
was extracted.  Successful excision of the transgenes was confirmed by performing PCR reactions 
on peripheral blood DNA with primers for the loxp sites.   
 
 Forward Reverse 
loxp 5’- CTT CGT ATA ATG TAT 
GCT ATA CG -3’ 
5’- TCG TAT AGC ATA 
CAT TAT ACG -3’ 
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Peripheral blood mononucleocytes were also resuspended in PBS and analyzed using the FACS 
Calibur for expression of YFP.  Development of disease was assessed by the presence of Mac1+ 
Gr1+ cells in the peripheral blood and Gr1+ cKit+ cells in the bone marrow by flow cytometry.  
Mice were monitored for lethargy, hunching, weight loss, and sacrificed and analyzed upon 
moribund.  Bone marrow was flushed from the femurs and tibias, passed through a 70uM filter to 
obtain single cell suspensions, and red blood cells were lysed with ammonium chloride buffer.  
The bone marrow cells were then stained with a variety of cell surface markers for flow 
cytometry analysis.  Hematoxylin and eosin staining of formalin-fixed tissues and organs such as 
the bone marrow and spleen was performed.  Blood smears were also obtained and stained with 
Wright-Giemsa stain.   
 
Antibodies and FACS analysis  
Antibodies used for peripheral blood analysis were obtained from eBioscience and include the 
following: Mac1, Gr1, B220 and CD3.  Bone marrow lineage cocktail includes the following 
biotinylated antibodies: Gr1, Ter119, B220, CD3.  Bone marrow cells were also stained with 
strepavadin-V500, cKit-PE-CF594, Sca1-APC-Cy7, CD16/32-AF700, CD34-PacBlue, FLT3-
APC, CD150-Qdot405 (BioLegend), CD48-PE, and IL7R-PerCP-Cy5.5 for analysis of 
hematopoietic stem and progenitor cell populations.  FACS analysis was performed on the FACS 
Caliber and the LSR II (BD Biosciences) and analyzed using FlowJo software (FlowJo).  
 
Bone marrow transplantation 
Bone marrow from unexcised SmoM2; FLT3-ITD; Mx1Cre mice were obtained by flushing the 
tibia and femur bones with PBS, and then passing the bone marrow cells through a 70uM filter.   
5 x 106 whole bone marrow cells were transplanted into lethally irradiated recipients through 
retroorbital injections.  These recipients are congenic C57BL/6 CD45.1+ female mice of 4 – 6 
weeks of age, treated with a split dose of 1200 rads of lethal total body irradiation – 800 rads and 
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400 rads about 3 hours apart, prior to transplantation.   4 weeks following bone marrow 
transplantation, chimerism of the mice were determined by staining peripheral blood with CD45.1 
and CD45.2 antibodies, and analyzing percentage of CD45.2 by flow cytometry.  Following 
confirmation that all mice should have at least 50% chimerism, poly(I:C) was then admininistered 
in 5 doses every other day, similar to transgenic animals as previously described, to excise the 
transgenes in the engrafted CD45.2 population.   
 
In vivo BrdU analysis 
In vivo BrdU incorporation experiments were conducted using the FITC BrdU Flow kit (BD 
Biosciences).  SmoM2; FLT3ITD; Mx1Cre animals were injected intraperitoneally with 150ug of 
BrdU solution about 3 months after they were induced with poly(I:C).  The mice were sacrificed 
10 hours after administration of BrdU, and bone marrow was collected from the femurs.  Cell 
surface staining was performed on whole bone marrow cells obtained from one femur prior to 
fixation, permeabilization, DNase treatment and then staining was performed with anti-BrdU 
antibody according to instructions provided in the manufacturer’s protocol.  At least 3 
independent experiments were conducted using littermate controls.    
 
Quantitative Real-time PCR analysis 
Total RNA was extracted using the RNeasy Plus Mini kit (Qiagen), and used for cDNA synthesis 
using Superscript III reverse transcriptase (Invitrogen).  qRT-PCR was carried out using SYBR 
Green and Taqman mastermixes using the following primers (ABI).  Gene expression levels were 
normalized against mouse Rps16 and human Beta-Actin expression and compared to wild type 
control using the ΔΔCT method of analysis.         
 
SYBR Green qRT-PCR primer sequences: 
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 Forward Reverse 
Mouse Flt3 5’- GCT CTG TCT CCC CTT 
CAT TG -3’ 
5’- CCA GGA CCT TCC 
CAA ACT CT -3’ 
Mouse Rps16 5’- CTT GGA GGC TTC 
ATC CAC AT -3’ 
5’- ATA TTC GGG TCC 
GTG TGA AG -3’ 
Human GLI1 5’- GGC TGC AGT AAA 
GCC TTC AGC AAT -3’ 
5’- TGC AGC CAG GGA 
GCT TAC ATA CAT -3’ 
Human Beta-Actin 5’- ATC CAG GAA ACT 
ACC TTC AAC TCC AT -3’ 
5’- CAT ACT CCT GCT TGC 
TGA TCC ACA TC -3’ 
  




FACS sorting of KSL and GMP cells 
For FACS sorting of KSL and GMP cells, whole bone marrow was first collected by obtaining 
hind limbs, hips and spine bones and crushing them in 2%FBS/PBS using a mortar and pestle.  
Lineage-negative cells were isolated using a mixture of biotin-labeled monoclonal antibodies 
against CD3e, B330, Gr1 and TER-119.  The cells were then incubated with anti-biotin micro-
beads (Miltenyi Biotec) for 20 mins at 4oC, and washed with PBS.  The cell pellet was 
resuspended in 500ul of Miltenyi buffer, and lineage positive cells were depleted by passing the 
cell suspension through a LD column attached to a Miltenyi AutoMACS magnetic separator 
(Milteni Biotec).  Lineage negative cells were then immunostained with streptavidin, cKit, Sca1, 
IL7R, CD34, CD16/32 antiobodies (eBioscience).  KSL (cKit+ Sca1+ Lin-) and GMP (cKit+ 
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KSL and GMP cells were FACS sorted (BD Aria) from wildtype, FLT3-ITD and SmoM2; FLT3-
ITD animals at approximately 3 months of age, or when SmoM2; FLT3-ITD animals were 
moribund.  Total RNA from these cell populations were extracted using the RNeasy Plus Micro 
kit (Qiagen), and hybridized onto the Affymetrix Mouse genome 430 2.0 array (Affymetrix).  
Gene set enrichment analysis (GSEA) was then performed.122  
 
Statistics 
Log-rank (Mantel-Cox) test p-values for the Kaplan-Meier survival curves were generated using 
GraphPad Prism.  All other p values were calculated using an unpaired two-tail Student’s t test, 
unless otherwise specified.  All data were collected from at least 3 independent experiments, and 




Hedgehog signaling pathway is clinically relevant in human AML 
To validate the presence of Hh signaling in human myeloid disease progression, we obtained 
patient samples at various stages of disease and examined Hh target gene expression by qRTPCR.  
In patients with CML, there were consistently higher levels of GLI1 and PATCH1 gene 
expression upon disease progression from chronic phase to blast crisis compared to normal 
hematopoietic stem cells (Figure 4.1A).  In addition, 4 out of 6 patients who progressed from 
myelodysplastic syndromes (MDS) to secondary AML had 2 to 9 fold higher levels of GLI1 and 
PATCH1 upon developing AML (Figure 4.1B).  Intriguingly, patients with FLT3-ITD AML also 
had significantly higher levels of GLI1 expression compared to normal human CD34+ bone 
marrow cells (Figure 4.1C), suggesting the relevance of Hh signaling in FLT3-ITD AML.  
Although not much is currently known about the precise role of Hedgehog signaling in human 
acute myeloid leukemia, we have shown evidence for the clinical relevance of Hedgehog 
signaling in human myeloid leukemia progression and advanced human FLT3-ITD AML, and 
speculate that Hh signaling may play a role in accelerating disease progression.  To further 
mechanistically investigate our hypothesis that Hedgehog signaling plays a role in myeloid 
disease progression and transformation, we generated a novel mouse model of myeloid disease 
progression by conditional activation of both Hh signaling and FLT3-ITD. 
 
 
Figure 4.1: Hedgehog signaling increases with disease progression and transformation in 
human myeloid malignancies  
(A)Relative Hedgehog pathway target gene expression in CML patients 
(B)Relative Hedgehog pathway target gene expression in 6 secondary AML patients 
(C)Relative GLI1 expression by qRTPCR in human FLT3-ITD AML samples compared to 







SmoM2; FLT3-ITD; Mx1Cre mice die rapidly of acute myeloid leukemia 
Initially identified in human basal cell carcinoma, the activating mutation W535L in human 
Smoothened (SMOM2) causes constitutive, ligand-independent activation of the Hedgehog (Hh) 
pathway.99 To investigate whether Hh signaling causes disease progression, we used a previously 
described mouse model R26-SmoM2 in which a cDNA fragment encoding the SmoM2-YFP 
fusion protein was targeted into the ubiquitously expressed Rosa26 locus (R26) behind a stop 
cassette flanked by Loxp sites.123 The yellow fluorescent protein (YFP) fused at the C terminus of 
SmoM2 has been shown to not interfere with its activity in neural epithelium and provides a tool 
to trace the lineage of all Cre-expressing cells and their progeny.124 To activate Hh signaling 
during definitive hematopoiesis, we crossed the R26-SmoM2 mice with Mx1Cre transgenic 
mice.125 These mice have normal hematopoiesis.  To investigate the role of Hh signaling in 
myeloid disease progression, we crossed the SmoM2; Mx1Cre mice with a previously established 
mouse model of chronic fatal myeloproliferation by a knock-in of FLT3-ITD.121 FLT3-ITD; 
Mx1Cre mice develop fatal myeloproliferative disease with a median survival of 10 months, but 
never transform to acute leukemia.  The FLT3-ITD knock-in mice were generated by the 
insertion of an 18 base pair human internal tandem duplication (ITD) mutation into the 
juxtamembrane domain of murine FLT3 behind an inverted neo cassette flanked by loxp sites.  
SmoM2; FLT3-ITD; Mx1Cre mice generated from the cross were treated with poly(I:C) upon 
weaning to induce the transgenes post-natally in the hematopoietic system.   
 
Genotyping was confirmed by PCR (Supplementary Fig 1), and successful excision of the FLT3-
ITD and SmoM2 alleles were determined by PCR and flow cytometry analysis of peripheral blood 
(Supplementary Fig 2).  Intriguingly, while Hedgehog signaling has been found to have no impact 
on normal adult hematopoiesis, we found that inducing constitutively active Hedgehog signaling 
via SmoM2 together with FLT3-ITD causes rapidly fatal acute myeloid leukemia with 100% 
penetrance.108, 109  SmoM2; FLT3-ITD animals died in 3 months compared to FLT3-ITD animals 
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(Figure 4.2A).  The disease was characterized by increased bone marrow cellularity (Figure 
4.2B), spleen weights and sizes (Figure 4.2C), elevated white blood cell counts (Figure 4.2D) in 
moribund SmoM2; FLT3-ITD animals compared to age-matched controls.  There was also an 
increased population of Mac1+ Gr1+ myeloid cells in the peripheral blood (Figure 4.2E) and 
accumulation of Gr1mid cKit+ cells in the bone marrow (Figure 4.2F).  Hematoxylin and eosin 
staining of the spleen and bone marrow showed complete effacement of splenic architecture and 
accumulation of immature myeloid cells in both organs.  Bloods smears showed accumulation of 
immature leukemic blasts, and are suggestive of acute myeloid leukemia (Figure 4.2G).  
Furthermore, there was infiltration of similar immature myeloid cells into non-hematopoietic 
organs such as the liver and lung in the moribund SmoM2; FLT3-ITD animals (Supplementary 
Figure 3).  According to the Bethesda proposals for classification of nonlymphoid hematopoietic 
neoplasms in mice as determined by the hematopathology subcommittee of the Mouse Models of 
Human Cancers Consortium, the SmoM2; FLT3-ITD mice have an MPD-like myeloid leukemia, 
as characterized by rapid death in the primary animal, at least 20% immature myeloid blasts in 
the peripheral blood, infiltration of myeloid cells into non-hematopoietic organs, and mature 
myeloid cells in the peripheral blood.126  
 
To verify that Hedgehog signaling is active in the animals, we looked at the levels of gene 
expression of Gli1, a target of the Hedgehog signaling pathway, by qRTPCR, in bone marrow 
cells.  Animals harboring the SmoM2 allele show significantly elevated Gli1 expression in the 
bone marrow, suggesting that Hedgehog signaling is driving the disease phenotype (Figure 4.2H).  
Loss of heterozygousity of the wild-type FLT3 allele has been reported to contribute to 
transformation and progression of disease.127 We observed by PCR analysis of bone marrow 
samples that the SmoM2; FLT3-ITD mice did not have the loss of heterozygousity despite 
disease transformation, implying that Hedgehog signaling may be facilitating a different 
mechanism to FLT3 mediated disease progression (Supplementary Fig 4).    
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Figure 4.2. SmoM2; FLT3-ITD; Mx1Cre animals die rapidly of acute myeloid leukemia  
(A)Kaplan Meier survival curve of transgenic animals (log-rank P<0.001) 
(B)Bone marrow cellularity of animals at around 3 months after PIPC (n=3 to 7 for each 
genotype) *p<0.05, **p<0.01 
(C)Spleen weights and representative spleens at 3 months **p<0.01 
(D)White blood cell counts at 3 months ***p<0.001 
(E)FACS analysis of disease phenotype in peripheral blood.  Bar graphs depict percentage of 
Mac1+ Gr1+ cells in peripheral blood. *p<0.05 ***p<0.001 
(F)FACS analysis of disease phenotype in bone marrow.  Bar graphs depict percentage of Gr1mid 
cKit+ cells in total bone marrow. **p<0.01 
(G)Hematoxylin and eosin (H&E) staining of spleen, bone marrow.  Wright-Giemsa staining of 
peripheral blood smear.  

































Myeloid progenitor compartments are expanded in diseased SmoM2; FLT3-ITD; Mx1Cre mice 
To characterize the disease phenotype on a cellular level, we examined the hematopoietic stem 
and progenitor subsets in the bone marrow by FACS analysis.  Bone marrow was harvested from 
the femur and stained with cell surface markers.  On examination of hematopoietic stem and 
progenitor cell populations, the SmoM2; FLT3-ITD mice consistently showed an increase in 
lineage negative progenitors.  Although there was no significant difference in the number of KSL 
cells – a population enriched for multipotent hematopoietic stem cells, the myeloid progenitors 
and GMPs were significantly expanded by 2-fold in the SmoM2; FLT3-ITD mice compare to 
FLT3-ITD mice (Figure 4.3A, B).  On further examination of more primitive hematopoietic stem 
cell populations within the KSL compartment by FLT3 and CD34 expression, there were no 
significant differences in the frequencies of long-term HSC (LT-HSC), short-term HSC (ST-
HSC), and MPP cells.  The CMP compartment was also not significantly expanded 
(Supplementary Fig 5).  A recent report showed that the FLT3-ITD myeloproliferative neoplasm 
was caused by increased proliferation in the normally quiescent primitive LT-HSC and SLAM 
(Lin- CD150+ CD48-) cells, leading to depletion of these primitive hematopoietic stem cells.128 
Compared to FLT3-ITD mice, the SmoM2; FLT3-ITD mice have a smaller population of Lin- 
CD150+ CD48- cells.  This suggests that Hedgehog signaling may contribute to disease 
progression by expanding the myeloid progenitors at the expense of primitive hematopoietic stem 















Figure 4.3. Myeloid progenitor compartments are expanded in diseased SmoM2; FLT3-
ITD; Mx1Cre animals  
(A)Representative FACS plots depicting relative percentage of stem and progenitor (Lin- Sca1+ 
cKit+), myeloid progenitor (Lin- Sca1- cKit+), GMP (Lin- Sca1- cKit+ CD34+ CD16/32+), CMP 
(Lin- Sca1- cKit+ CD34+ CD16/32-) and MEP (Lin- Sca1- cKit+ CD34- CD16/32-) cells in bone 
marrow of transgenic animals.    
(B)Bar graphs show number of cells from each population per femur from at least 3 animals per 







SmoM2 and FLT3-ITD cooperate to cause accelerated disease in a cell autonomous manner 
To determine if the observed disease phenotype in the SmoM2; FLT3-ITD mice was due to the 
direct expression of both transgenes in the hematopoietic cells in the bone marrow or if it was 
influenced by the microenvironment, we transplanted unexcised CD45.2 SmoM2; FLT3-ITD; 
Mx1Cre bone marrow into lethally irradiated wild-type CD45.1 recipients and administered the 
chimeric mice with poly(I:C) 3 weeks after transplant (Supplementary Fig 6).  Successful 
excision of the transgenes was verified in the chimeric animals by PCR and flow cytometry of 
peripheral blood.  These mice developed disease only in the CD45.2 SmoM2; FLT3-ITD 
population, and not in the normal host CD45.1 population.  Compared to transgenic SmoM2; 
FLT3-ITD mice characterized in the previous figure, we observed that these chimeric mice died 
in a similar time frame, with the same blood and bone marrow phenotype in the CD45.2 
population, suggesting that the disease occurs in a cell autonomous manner in hematopoietic 
cells.   
 
Myeloid progenitors proliferate more in mice with both FLT3-ITD and SmoM2 compared to 
FLT3-ITD alone  
To mechanistically explain the increased cellularity and myeloid progenitor expansion resulting 
in disease acceleration and rapid death in mice with both SmoM2 and FLT3-ITD alleles, we 
decided to look at the proliferative capacity of these myeloid progenitors by BrdU incorporation 
in vivo.  Transgenic animals at 3 months post poly(I:C) induction were injected with BrdU and 
bone marrow was harvested 10 hours later and co-stained with cell surface markers and anti-
BrdU antibody to determine proliferation in different myeloid progenitor compartments.  While 
there were no significant differences in BrdU incorporation in the more primitive hematopoietic 
stem cell compartments (Supplementary Fig 7), SmoM2; FLT3-ITD myeloid progenitor cells had 
a higher level of BrdU incorporation compared to mice having just FLT3-ITD alone (Figure 
4.4A, B).   
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We also performed a gene expression profiling by microarray of FACS-sorted KSL and GMP 
cells from 3 month old wild-type, FLT3-ITD and SmoM2; FLT3-ITD mice.  Gene Set 
Enrichment Analysis (GSEA) of the microarray data indicated that there was significantly 
enhanced proliferation as well as Stat5 signaling in SmoM2; FLT3-ITD mice compared to FLT3-
ITD alone (Figure 4.4C).122  The Stat5 signaling pathway is the main downstream target of FLT3-
ITD, and has been shown to play a role in maintaining the survival and proliferation of myeloid 
leukemia cells.  Compared to wild-type mice, FLT3-ITD mice have increased Stat5 signaling, as 
expected.  Our data suggests that Hedgehog signaling may enhance the proliferation and 
expansion of myeloid progenitors by amplifying FLT3-ITD mediated Stat5 signaling.  
Specifically, JunB and Krüppel-like factor 6 (Klf6) genes were found to be consistently 
upregulated in the SmoM2; FLT3-ITD samples.  Although these genes function as tumor 
suppressors in certain cancers, these effects are highly dependent on cell type and tissue.  
Interestingly, cooperation between GLI and JUN family transcription factors in human 
keratinocytes suggests that the GLI-JUN interaction may play a significant role in tumor 
progression.129 In addition, KLF6 has been reported to play a role in developmental 
hematopoiesis, and similar to Hh, it may also cooperatively regulate the oncogenic EGFR 
pathway.130, 131 We validated these genes by performing qRTPCR on sorted GMPs (data not 
shown).  Interestingly, we also observed that Flt3 gene expression levels were significantly 
higher in the GMPs of SmoM2; FLT3-ITD mice compared to FLT3-ITD only mice (Figure 
4.4D).  This suggests that Hh signaling can augment the already constitutively active FLT3 
signaling to accelerate disease progression.  This in turn enhances downstream Stat5 signaling. 
While Hedgehog signaling has no impact on normal hematopoiesis, it appears to contribute to 
disease progression in the context of existing oncogenes.  In this case, Hedgehog signaling 
cooperates with and amplifies FLT3-ITD mediated signaling pathways to cause myeloid disease 
acceleration by increasing proliferation of myeloid progenitors.     
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Figure 4.4. Myeloid progenitors proliferate more in mice with both FLT3-ITD and SmoM2 
compared to FLT3-ITD alone  
 
(A)Representative FACS plots depicting relative percentage of cells with BrdU incorporation in 
GMP (Lin- Sca1- cKit+ CD34+ CD16/32+), CMP (Lin- Sca1- cKit+ CD34+ CD16/32-) and 
MEP (Lin- Sca1- cKit+ CD34- CD16/32-) compartments 
(B)Bar graphs show percentage of cells with BrdU incorporation from each population *p<0.05, 
n=3 for each genotype 
(C)GSEA analysis of SmoM2;FLT3-ITD compared to FLT3-ITD bone marrow cells 
(D)qRT-PCR of relative mouse FLT3 gene expression levels in sorted mouse GMP cells. 








Myeloproliferative disease progression 
Myeloproliferative neoplasms are hematologic disorders characterized by terminal myeloid cell 
expansion in the peripheral blood, with a long-term risk of transformation to acute leukemia.  
Generally the incidence of myeloproliferative diseases increases with age, and patients inevitably 
develop secondary myeloid malignancies such as acute myeloid leukemia (AML).  Conventional 
high dose chemotherapy is both a toxic and ineffective form of therapy.  Bone marrow 
transplantation may present a cure, however most patients are at an advanced age or have 
coexisting diseases and are therefore poor transplant candidates.  Aberrant signal transduction 
appears to be responsible for disease pathogenesis in proliferative myelodysplastic syndrome 
(MDS) subtypes.  Most of what is currently known about myeloid disease progression came from 
studies on and treatment of chronic myeloid leukemia (CML).  CML is a clonal 
myeloproliferative disease characterized by an accumulation of myeloid cells.  In the initial 
chronic phase (CP), there is accumulation of myeloid progenitors and mature myeloid cells in the 
blood and extramedullary tissues.132 Most patients are diagnosed at this stage; CML-CP is also 
characterized by the presence of the BCR-ABL1 fusion oncogene, also known as the Philadelphia 
chromosome.  The advance phase of CML includes an initial accelerated phase (AP), where 
patients may still respond to treatment, and a subsequent more aggressive blastic phase (BP) 
characterized by a maturation arrest with a median survival of 6 months.  Molecular mechanisms 
underlying disease progression from CP to BP are currently poorly understood.   Although the 
loss of p53 and reduplication of the Philadelphia chromosome are the most frequent abnormalities 
leading to the development of blast crisis, there are no well-characterized mechanisms and events 
that overwhelming contribute to disease progression.   Activating mutations in the receptor 
tyrosine kinase FLT3 is rare in MDS, but is associated with leukemia progression and frequently 
found in AML.  To study myeloid disease progression, we used the previously published FLT3-
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ITD; Mx1Cre mouse model, where animals developed fatal myeloproliferative disease over a 
prolonged time period, and bred it to a SmoM2 mouse, where Smo is driving constitutive Hh 
signaling.    
 
We generated a novel mouse model of myeloid disease progression by conditionally activating 
SmoM2 and FLT3-ITD in the hematopoietic system, and showed that increased Hedgehog 
signaling accelerated myeloid disease progression initiated by FLT3-ITD.  SmoM2; FLT3-ITD 
mice developed a rapidly fatal myeloid leukemia characterized by increased proliferation of 
myeloid progenitors.  Intriguingly, SmoM2 alone does not impact normal hematopoiesis, hence 
we provide evidence that a developmental signaling pathway such as the Hh pathway can 
function as a disease accelerator in the presence of an existing oncogene, in this case, FLT3-ITD.  
While disease acceleration and transformation in FLT3-ITD leukemias are often caused by the 
loss of the wild-type FLT3 allele, we show that the Hedgehog signaling pathway can also 
facilitate disease progression without the loss of heterozygousity and genetic instability.127, 133     
Disease progression also occurs in a cell autonomous manner in our model.   
 
Mechanisms of FLT3-ITD AML transformation 
Although specific lesions and mutations are known to cause AML, the mechanisms of disease 
pathogenesis are still unclear.  Evidence from retroviral bone marrow transplantation and 
transgenic mouse models have shown that additional oncogenes and mutations are required to 
cooperate with FLT3-ITD mutations to cause leukemia.  Particularly, FLT3-ITD mutations 
together with chromosomal translocations such as PML-RARa, MLL-AF9, and inv(16) have been 
shown to cause AML as demonstrated using retroviral bone marrow transplantations.134-136 These 
models were used to collectively illustrate that AML is the consequence of cooperation between 
at least two classes of mutation, one that impairs hematopoietic differentiation, and a second that 
confers a proliferative and/or survival advantage.  Though these studies have been informative 
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about the biology of FLT3-ITD leukemia, these retroviral bone marrow transplantation models do 
not physiologically recreate the levels of oncogene expression.  Nonetheless, one of the known 
mechanisms of disease progression in FLT3-ITD AML is the loss of the FLT3-WT allele by 
acquired segmental uniparental disomy.  In recent years, several groups have generated transgenic 
mouse models showing FLT3-ITD cooperation with other genetic lesions to cause AML, with a 
loss of heterozygousity.  Specifically, knock-in of both FLT3-ITD and Nup98HoxD13 causes an 
aggressive AML with loss of heterozygousity.137 Several groups have showed that nucleophosmin 
mutations such as NPM1C and NPMc+ also cooperates with FLT3-ITD to cause AML with loss of 
heterozygousity.138, 139  Zorko et al also showed that MLL-PTD cooperates with FLT3-ITD to 
cause leukemia in a FLT3 dosage dependent effect.140   
 
Role of developmental signaling pathways in leukemia 
Recent studies of developmental signaling pathways in leukemia have also shed some light on 
mechanisms of disease pathogenesis in leukemia.  Several of these developmental pathways that 
have gone awry give rise to leukemogenesis by regulating the maintenance and self-renewal of 
leukemia initiating cells.  Notably, the Wnt/ β-catenin signaling pathway has been reported to 
play a significant role in regulating leukemic stem cells in CML as well as AML.141, 142 Recently, 
Scheller et al showed that Wnt/β-catenin signaling can contribute to CML progression to blast 
crisis and drug resistance by driving self-renewal and myeloproliferation.143  In CML, TGFb-
FOXO signaling also plays a role in maintaining leukemia initiating cells.144  On the other hand, 
while activating mutations of Notch1 have been found in human T-cell ALL, and Notch signaling 
is also implicated in the pathogenesis of APL, Notch signaling has been identified as a tumor 
suppressor in AML.145, 146 Notch pathway activation inhibits growth of AML by disrupting 
homeostasis and differentiation of disease initiating cells.147, 148 In a similar differentiation-
inducing approach, elevated Akt/FOXO signaling found in AML patients, were required to 
maintain leukemia initiating cells; decreasing FOXO3 can increase myeloid maturation and 
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induce apoptosis in disease initiating cells.149 Intriguingly, FLT3-ITD mutations have been 
reported to cooperate with Wnt signaling in leukemia, and the signal transduction pathways 
synergize in myeloid transformation.150 Wnt pathway activity also plays a role in modulating the 
sensitivity of FLT3 pathway inhibitors, suggesting the clinical significance of understanding the 
role of developmental signaling pathways in leukemia.151     
 
Interestingly, these developmental signaling pathways have not been shown to overtly initiate 
malignancy formation.  Wnt signaling has been shown to be dispensable for adult HSC 
maintenance.152 While Notch signaling may be essential for HSCs during fetal development, and 
also plays a role in the lymphoid lineage, its inactivation results in a myeloproliferative disease 
and not AML.  Similarily, though Hh signaling has been implicated in both normal adult and 
embryonic hematopoiesis, the precise role of Hh signaling has been controversial, depending on 
the stage of development, cell types examined, physiological state and methods of interrogation.  
Mouse models of Hh modulation have been used to elucidate the role of Hh signaling in the 
hematopoietic system.  Examples include activation of Hh signaling by deletion of Ptch1 and 
Smo dependent Hh signaling transgenic mouse models.  While studies by Dierks et al and Zhao et 
al showed that deletion of Smo in the mouse affected hematopoiesis, two seminal studies 
challenged this view in 2009 when they both suggested that Smoothened was dispensable for 
adult hematopoiesis, based on the use of an inducible conditional Smo knockout model in adult 
mice.108, 109 A Cre recombinase under the control of the myxovirus-resistance 1 (Mx1) gene 
promoter (Mx1-Cre) when stimulated with poly(I:C), allowed for interferon-inducible Smo 
deletion in the hematopoietic system.125 The deletion of Smo in adult mice did not affect 
hematopoiesis.  The positive downstream effector of the Hh pathway, Gli1, however, did have an 
effect on hematopoiesis.   Merchant et al found that while Gli1 null mice had an expanded LT-
HSC compartment, there was impaired myeloid differentiation and defective response to stress in 
the proliferative progenitor compartments.153 
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Interaction between signaling pathways in cancer development 
These studies suggest that while these pathways play a role in maintaining self-renewal in disease 
initiating cells, their contribution to advance disease and poor prognosis may be in the form of 
accelerating existing oncogenic lesions by enhancing cross talk between signaling transduction 
pathways.  Recent evidence suggests that activation of Hh signaling in neoplasms may result 
from the integration of multiple deregulated oncogenic signaling inputs in the final signaling 
effectors of the pathway, the GLI transcription factors.  Growth factors such as platelet-derived 
growth factor, epidermal growth factor, and insulin-like growth factor 1 increase activation of the 
Hh pathway by way of activating the PI3K-AKT pathway.  Interplay between Hh pathway and 
NF-kB, RAS-RAF-MEK, TGF-β, and notch pathways have also been reported in several cancers.  
An understanding of how major oncogenic pathways interact with each other to drive 
tumorigenesis will enhance the development of more effective and targeted therapies.  We 
speculate that one of the ways disease progression can occur in leukemia is by cross talk between 
different signaling pathways.  A prominent example would be the evidence of cross talk between 
the Hh and the EGFR pathways shown in skin cancers. Coactivation of EGFR and Gli1 resulted 
in the activation of selected GLI target genes.  This cooperation also was mediated by the 
activation of MEK/ERK signaling by EGFR.   In FLT3-ITD driven leukemias with upregulated 
Hh signaling, we show that cross talk between the FLT3 tyrosine kinase signaling pathway and 
Hh pathway can enhance Stat5 signaling and proliferation.  Intriguingly, JunB and Klf6, both 
found to be significantly upregulated in SmoM2; FLT3-ITD mice, have also been shown to be 
implicated in the epithelial-mesenchymal transition in response to TFG-β, a known mechanism of 
disease progression in solid tumors.154    
 
We show in our model that a developmental signaling pathway that has no effect on 
hematopoiesis on its own can cooperate with FLT3-ITD to cause AML.  Disease progression 
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occurs rapidly when Hh signaling cooperates with and augments FLT3-ITD signaling to enhance 





Supplementary Figure 1: Genotyping of transgenic mice by PCR 
PCR using specific primers were run using genomic DNA extracted from mouse tail clippings as 






Supplementary Figure 2: Verification of excision of transgenes in mouse model 
Peripheral blood was obtained via the retro-orbital sinus 3 weeks after the last poly(I:C) injection.  
Genomic DNA was extracted from peripheral blood and PCR reactions were performed to 
determine if the FLT3-ITD transgene was successfully excised.  Peripheral blood was also lysed 
by RBC lysis buffer, and analyzed by flow cytometry to detect YFP, as an indication of 










Supplementary Figure 3: Leukemic infiltration in non-hematopoietic organs 
Necropsies were performed on SmoM2; FLT3-ITD animals at the time of their death from 
leukemia, and the extent of mononuclear and myelocytic cell infiltration was determined.  





Supplementary Figure 4: No evidence of loss of heterozygousity in diseased mice 
DNA was extracted from whole bone marrow as well as sorted GMP cells of SmoM2; FLT3-ITD 
mice at their time of death from leukemia, and PCR was performed using primers that detect 






Supplementary Figure 5: No significant differences in primitive HSC frequencies  
Whole bone marrow cells from moribund SmoM2; FLT3-ITD animals and their littermate 
controls were stained with cell surface antibodies and analyzed on the FACS Calibur to determine 






Supplementary Fig 6: Cell autonomous disease model 
SmoM2; FLT3-ITD chimeric mice were administered poly(I:C) to induce the SmoM2 and FLT3-
ITD transgenes in the CD45.2 population.  SmoM2; FLT3-ITD disease phenotype is recapitulated 
in the CD45.2 population.  The SmoM2; FLT3-ITD chimeric animals also die in a similar time 





Supplementary Fig 7: BrdU incorporation in HSC compartments 















This pivotal association of Hh signaling in oncogenesis suggests that targeting components of the 
Hh pathway can be an enticing therapeutic strategy in managing cancers.  Given its role as a 
positive effector in the pathway and in several malignancies, Smoothened has emerged to be a 
prominent target.  Indeed, the discovery of cyclopamine, a natural compound that can inhibit Hh 
signaling by direct binding to Smo, provides evidence that the Hh pathway is susceptible to 
inhibition by exogenous small molecules, especially at the level of Smoothened.155, 156 However, 
due to the limited potency and poor oral solubility of cyclopamine, it has not been used in the 
clinic.157 Nevertheless, since the discovery of cyclopamine, several more potent and specific Smo 
inhibitors have been developed and are currently in clinical trials for the treatment of a variety of 
cancers158.  Vismodegib, an orally active Smo antogonist used to treat advanced basal cell 
carcinoma (BCC), has become the first synthetic Smo inhibitor to be approved by the FDA in 
2012.159 Vismodegib was also used in a patient resulting in regression of advanced 
medulloblastoma.160 Despite these successes, a subsequent study reported that other solid tumors 
did not respond to Vismodegib.161 Vismodegib did not show sufficient efficacy in metastatic 
colorectal cancer and advanced ovarian cancer in Phase II trials.162, 163 Saridegib, another Smo 
inhibitor developed by Infinity, also failed to show an overall survival benefit in metastatic 
pancreatic cancer.164 The lack of positive results could be explained by the fact that these patients 
had very advanced, multiply treated malignancies, and were monitored over a relatively short 
follow-up time.  However, these failures also stem from a lack of understanding of how Hh 
signaling is contributing to disease in these other cancers.  In basal cell carcinoma, Hh signaling 
has been shown to be the cause of the disease, however in other cancers, the activation of Hh 
signaling may be one of several drivers of disease pathogenesis.157 Furthermore, Hh signaling 
appears to have distinct mechanisms of action in different tumor types and environments.  
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Ligand-independent activation of the pathway drives malignancies such as BCC and 
medulloblastoma through cell intrinsic mutations in PTCH and SMO, as shown using mouse 
models.101, 102 In particular, recurrent mutations in SMO include L412F, R562Q (SMO M1) and 
W535L (SMO M2), and functional studies have demonstrated that such mutations, which result in 
aberrant activation of Hh signaling, promote tumorigenesis.99  Hh signaling can also occur in an 
autocrine or paracrine manner between tumor cells and its microenvironment by ligand 
overexpression, such as in glioblastoma, lymphoma and pancreatic cancer.165 Evidence 
supporting ligand dependent paracrine signaling has accumulated from studies in human tumor 
xenograft mouse models of pancreatic and colorectal cancer that highly express Hh ligand, and 
increased Hh target gene expression is observed in the infiltrating mouse stromal cells.166 
Additionally, in reverse paracrine signaling, another ligand-dependent mechanism, the bone 
marrow stroma in cancers such as lymphomas and multiple myelomas is the source of Hh ligand, 
which then activates Hh signaling in the tumor.167 Nevertheless, the precise molecular 
mechanisms of how Hedgehog pathway stimulation positively regulates tumor growth are not 
completely understood, given an appreciation of the varying contextual roles of the signaling 
pathway.  Furthermore, the role of Hh inhibitors in cancers where components of the pathway are 
not mutated is unclear.  New mutations in Smo can also be acquired, resulting in resistance to 
Smo inhibitors such as the case of Vismodegib in the treatment of medulloblastoma.168 
Nevertheless, despite a lack of mechanistic understanding of Hh signaling in cancer, these Smo 
inhibitors have been fairly well tolerated and have little to no hematologic toxicities.169 Most of 
the existing pre-clinical studies using Smo inhibitors show moderate tumor growth inhibition in 
xenograft and transgenic mouse models, suggesting that Hh inhibition alone may not be 






The impressive response of chronic myelogenous leukemia patients to BCR-ABL tyrosine kinase 
inhibitors (TKI) generated enthusiasm for molecularly targeted therapies in malignancies 
dependent on constitutively activated kinase signaling. FLT3 inhibitors have begun to show 
promise in clinical trials, and there is currently great enthusiasm that small molecule tyrosine 
kinase inhibitors will transform the care of a large number of AML patients.170 However, 
similarly to the development of resistance to imatinib from acquisition of point mutations in 
BCR-ABL, mutations in FLT3-ITD have been observed in AML patients treated with TKIs.171  
The development of these FLT3 inhibitors has been hampered by weak and transient inhibition.  
Furthermore, patients have developed resistance to these inhibitors, largely by acquiring other 
tyrosine kinase mutations.172   
 
Sorafenib, a small molecule inhibitor that targets a number of serine/threonine and receptor 
tyrosine kinases is the first oral agent approved for the clinical treatment of advanced renal and 
hepatocellular cancers.173, 174 Sorafenib has been reported to directly inhibit mutant FLT3 in the 





Cell culture and drug treatment 
Human MV411 and Molm14 cell lines harboring the FLT3-ITD mutation were cultured in RPMI 
media supplemented with 10% FBS, 0.5% L-Glutamine and 0.5% Pen/Strep.  Both IPI 926 
(Infinity Pharmaceuticals) and Sorafenib (LC laboratories) were dissolved in 100% DMSO 
(Sigma).   Sorafenib was prepared as 10uM stock solutions in RPMI with 0.1% DMSO and stored 
at -800C.  The cell lines were treated with either 2.5uM of IPI 926 or 1nM of Sorafenib for 
MV411 cells and 3nM for Molm14 cells, or a combination of both.  Recombinant Shh ligand was 
purchased from R&D Systems and used at a concentration of 2ug/ml.  Cells were seeded at 
100,000 cells/ml and cultured in the 370C incubator for 3 days with the inhibitors.  Viable cell 
counts were obtained every 24 hours by the Trypan blue exclusion assay.   
 
Cell cycle analysis 
MV411 and Molm14 cells were washed with PBS following drug treatment.   The cell pellets 
were resuspended in PBS containing 0.6% NP40 (Sigma), 40ug propidium iodide and 2ug/ml 
RNase (Roche).  The mixture was vortexed and kept on ice for 15 minutes, following which cell 
cycle analysis was performed using the FACS Calibur (BD Biosciences) and analyzed using 
FlowJo software (Flow Jo).      
 
Apoptosis assay 
MV411 and Molm14 cells were washed with PBS following 3 days of drug treatment.   The cell 
pellets were resuspended in 100ul of 1X Binding buffer, and stained with AnnexinV-FITC 
antibody and PI according to manufacturer’s protocol (BD Biosciences).  Following staining, the 
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cells were immediately analyzed to determine the percentage of AnnexinV+ PI+ dead cells by 
flow cytometry on the FACS Calibur (BD Biosciences).   
 
Colony formation 
MV411 and Molm14 cells were treated with IPI 926, Sorafenib and a combination of both for 3 
days.  At day 3 after drug treatment, 500 cells from each treatment group was plated onto semi-
solid methycellulose media and incubated at 370C.  Total colony counts were obtained 7 days 
after plating.  Data is representative of 3 independent experiments.   
 
In vivo drug treatment  
IPI 926 (Infinity Pharmaceuticals) was formulated in a 5% β-cyclodextrin (Sigma) solution with 
deionized H2O according to manufacturer’s protocol.  Mice were given 20mg/kg of IPI 926 or the 
same volume of 5% β-cyclodextrin solution once a day for 16 days by oral gavage.  
 
Sorafenib (Bayer) was formulated in 100% DMSO (Sigma).  Mice were given 10mg/kg of 
Sorafenib or vehicle once a day for 16 days by oral gavage.  Vehicle solution consisted of 30% 
(w/v) Cremophor EL, 30% (w/v) PEG 400, 10% ethanol, and 10% glucose (all Sigma-Aldrich).  
Mice were also given the combined treatment of Sorafenib and IPI 926.  The vehicle treated 
group received both 5% β-cyclodextrin solution as well as the vehicle solution for Sorafenib.   
 
Statistics 
Log-rank (Mantel-Cox) test p-values for the Kaplan-Meier survival curves were generated using 
GraphPad Prism.  All other p values were calculated using an unpaired two-tail Student’s t test, 
unless otherwise specified.  All data were collected from at least 3 independent experiments, and 





Sorafenib and IPI 926 synergistically decrease leukemic cell growth in vitro and in vivo. 
In adult AML, activating mutations of the FLT3 tyrosine kinase in the form of internal tandem 
duplication insertions in the juxtamembrane domain or point mutations in the kinase domain are 
the most commonly found mutation.  FLT3-ITD mutations in particular are found in 
approximately 30% of de novo AML cases.  These patients with the mutation also have a poor 
prognosis, and are highly prone to relapse.  Therefore, there is a lot of interest in generating and 
using inhibitors that target the FLT3 signaling pathway.  However, the challenges to effectively 
using these inhibitors include resistance to tyrosine kinase inhibitors, emergence of kinase 
domain mutations, as well as dependence on other pathways.  Combining the use of these FLT3 
inhibitors with other treatment modalities and other pathway inhibitors may overcome some of 
these challenges.  To further investigate the functional relevance of Hedgehog signaling in human 
FLT3-ITD AML, we pharmacologically inhibit both the Hedgehog and FLT3 signaling pathways 
in human FLT3-ITD AML cell lines.  Sorafenib has been shown to have significant activity 
against FLT3-ITD in human cells.175  IPI 926 is a semi-synthetic small molecule antagonist of 
Smoothened currently in Phase 1 and 2 clinical trials.  We treated Molm14 and MV411 human 
leukemia cell lines, of which both harbor the FLT3-ITD mutation, with both Sorafenib and IPI 
926.  Interestingly, we observed that IPI 926 does not have any effect on the growth of the cancer 
cells.  While Sorafenib alone decreases cell growth over time, the combination of Sorafenib and 
IPI 926 further reduces cell growth in both the cell lines (Figure 5.1A).  This effect is specific 
given that Sorafenib does not impact the growth of HL60 cells, which have wild-type FLT3.  To 
determine if increased Hedgehog signaling can override the effects of Sorafenib, we treated the 
cells with recombinant Sonic Hedgehog (Shh) ligand.  In the presence of the Shh ligand, 
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Sorafenib was not as effective in decreasing cell growth (Figure 5.1B), suggesting that the effect 
is specific to Hh signaling.   
 
To investigate the mechanism of decreased cell growth and viability with combined Sorafenib 
and IPI 926 treatment, we examined apoptosis by AnnexinV and Propidium Iodide (PI) staining 
as well as cell cycle progression by PI staining in Molm14 cells.  There was a trend towards 
increasing AnnexinV+ PI+ cells when Sorafenib treatment is combined with IPI 926 (Figure 
5.1C), as well as a significant difference in cell cycle progression.  Sorafenib together with IPI 
926 caused more cells to arrest in G1 phase of cell cycle progression compared to just Sorafenib 
alone (Figure 5.1D).  The effects of combining Sorafenib and IPI 926 appear to be synergistic 
(Supplementary Fig 8).  These experiments were also performed using MV411 cells, which 
showed a similar result (data not shown).  There was also a significant decrease in the clonogenic 
growth of cells treated with both Sorafenib and IPI 926 compared to Sorafenib alone (Figure 
5.1E).  These results support the overall decrease in cell viability, and show that simultaneously 
inhibiting both the FLT3 and Hh signaling pathways in human FLT3-ITD AML cell lines can 
reduce leukemic growth.    
 74 
Figure 5.1. Sorafenib and IPI 926 synergistically decrease leukemic cell growth in vitro  
(A)Viable cell counts using Trypan Blue assay, of Molm14 and MV411 cell lines treated with IPI 
926 and Sorafenib, data from at least 4 independent experiments *p<0.05 
(B)Viable cell counts of Molm14 and MV411 cell lines treated with recombinant Shh ligand and 
Sorafenib, data from at least 3 independent experiments *p<0.05 
(C)Bar graphs showing percentage of AnnexinV+ PI+ cells in Molm14 cells treated with IPI 926 
and Sorafenib, data from 3 independent experiments. 
(D)Bar graphs showing percentage of cells in G1, S and G2 phases of cell cycle progression by PI 
staining in Molm14 cells treated with IPI 926 and Sorafenib, data from 3 independent 
experiments. *p<0.05 
(E)Bar graphs showing relative clonogenicity of MV411 and Molm14 cells treated with IPI 926 
and Sorafenib for 3 days and plated in methycellulose, data from at least 3 independent 


















To further test the efficacy of combining these inhibitors in vivo, we generated chimeric CD45.1 
mice engrafted with CD45.2 SmoM2; FLT3-ITD; Mx1Cre bone marrow, administered poly(I:C) 
to induce the transgenes, and delivered the drugs by oral gavage 3 months after induction of the 
transgenes (Supplementary Fig 6).  We confirmed that the transgenes were excised in these 
chimeric mice by PCR and flow cytometry, and also confirmed that they recapitulated the disease 
phenotype in CD45.2 bone marrow by flow cytometry.  These mice were treated with the drugs 
once a day consecutively for 16 days.  Immediately post-treatment, mice receiving both Sorafenib 
and IPI 926 showed a reduction in spleen sizes compared to the other treatment groups (Figure 
5.2A).  Mice treated with both Sorafenib and IPI 926 for 16 days also had better overall survival 
compared to just Sorafenib or IPI 926 treatment alone (Figure 5.2B), showing that combinatorial 
therapy by inhibiting both pathways simultaneously can rescue the animals from death from 
FLT3-ITD AML.     
 
Combinatorial therapy with Sorafenib and IPI 926 appear to reduce the growth of FLT3-ITD 
leukemia cells both in vitro and in vivo.  We provide rationale and evidence for combining the 
inhibitors in the clinic, as well as evidence that a developmental signaling pathway such as 


















Figure 5.2 Combined Sorafenib and IPI 926 treatment increases overall survival in vivo 
(A)Spleen sizes of drug treated animals immediately after 16 days of treatment 
(B)Kaplan Meier survival curve of animals treated with Hh and FLT3 pathway inhibitors. 










Limitations of FLT3 inhibitors  
Although FLT3 signaling remains a great therapeutic target, especially with FLT3-ITD being the 
most common mutation, responses are transient and leukemia progression invariably occurs.  
Single base mutations at the FLT3 tyrosine kinase domain (TKD) also leads to a gain of function, 
although its prognostic significance is less well defined because of its rarity.  There is compelling 
evidence that leukemia clones carrying both ITD and TKD mutations appear when resistance to 
FLT3 inhibitors occurs.  The FLT3 signaling pathway might have become refractory to inhibition 
or alternative survival pathways could have been activated in the leukemic cells.  Furthermore, 
FLT3-ITD+ cells might belong to a subclone in the leukemic cell population and new clones 
might emerge during leukemia progression and relapse.  Interestingly, the emergence of double 
ITD and TKD mutants can be recapitulated in vitro when FLT3-ITD+ leukemia cell lines are 
treated with mutagens and FLT3 inhibitors.  Furthermore, murine xenotransplantation models 
also suggest that, in some cases, the FTL3-ITD and TKD double mutants actually exist in minute 
amounts before treatment with FLT3 inhibitors, expand under the selection pressure of FLT3 
inhibition and become the predominant resistant clone(s) during the drug-refractory phase.  On 
the basis of this model of clonal evolution, a multipronged strategy using more potent FLT3 
inhibitors, and a combinatorial approach targeting both FLT3-dependent and FLT3-independent 
pathways, will be needed to improve treatment outcome. 
 
Limitations of Smo inhibitors 
The use of Hh inhibitors together with FLT3 inhibitors could potentially benefit patients with 
advance or relapsed FLT3-ITD AML, especially if inhibiting Hh has no effect on normal 
hematopoiesis.  Nevertheless, as canonical Smo function is associated with the primary cilium, 
and hematologic cells have been thought of to lack this cellular protrusion, this could argue 
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against the case of using Smo inhibitors in myeloid leukemias.  There is also increasing evidence 
of Smo-independent activation of Gli transcription activity by signaling pathways such as the 
RAS, MAPK and PI3K/AKT pathways.  Also, although Sorafenib works more precisely to target 
FLT3-ITD compared to FLT3-WT, it also targets a variety of other kinases that could activate 
downstream Hh activity.  Nevertheless, despite the approval of Vismodegib by the FDA for 
advanced basal cell carcinoma, and the promising clinical results for Smo inhibitors in 
medulloblastoma, the proof of concept in Hh ligand-dependent tumors in the absence of genetic 
alterations remains to be determined.  Existing pre-clinical data has showed modest tumor growth 
inhibition in cancer xenograft models and genetically engineered mouse models, thus Smo 
inhibition alone may not provide sufficient efficacy in these cancers, and combinations with other 
agents might be needed to achieve maximal benefit.    
 
Evidence for combinatorial therapy 
One of the most extensively studied combination partners for Smo inhibitors is gemcitabine for 
the treatment of pancreatic cancer.  The single-agent activity of Smo inhibitors on primary tumor 
growth in pancreatic cancer xenograft models is modest at best and seems to be mediated 
primarily through stromal pathway inhibition.166 Recently, in a genetically engineered mouse 
model of pancreatic cancer, it was proposed that saridegib sensitizes tumors to gemcitabine 
treatment through depletion of the tumor stroma.176 Moreover, the combination of cyclopamine or 
saridegib with gemcitabine was active in an orthotopic metastatic model of pancreatic cancer, 
putatively through combined cytoreductive and cancer stem cell mediated effects of gemcitabine 
and saridegib, respectively.177, 178 However, results from a phase 2 trial in patients with pancreatic 
cancer failed to show a benefit over single agent gemcitabine, highlighting the challenges of 
testing Smo inhibitors in patients without known driver mutations.   
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Additional support for combination strategies also stems from the growing body of preclinical 
data showing evidence of noncanonical activation of Hh signaling in tumors mediated through the 
PI3K-AKT pathway.179 Furthermore, the MEK–ERK–JUN signaling axis appears to be the driver 
for the crosstalk between the Hh and epidermal growth factor receptor (EGFR) pathways.180 The 
effects of combining EGFR and SMO inhibitors on tumors have been described in several in vitro 
preclinical models, including basal cell carcinoma, prostate cancer and glioblastoma.181, 182 The 
MEK–ERK pathway has also been shown to link mutant KRAS to Hh pathway activation in 
pancreatic cancer and melanoma.183, 184 These data highlight the potential of new combination 
opportunities for Smo inhibitors in cancers with unmet treatment needs.  Nonetheless, we have 
provided pre-clinical rationale using both in vitro and in vivo studies for potentially combining 







Supplementary Fig 8: Synergistic effects of Sorafenib + IPI 926 combined therapy 
Bar graphs show relative absorbance from MTT assay. n=3. *P<0.05  
Combination index of drug treatment is calculated to show synergistic interaction of Sorafenib 
and IPI 926 on Molm14 cells.  A similar effect was also observed using MV411 cells (data not 











CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS 
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Conclusions: 
In this dissertation, methods to study hematopoiesis in both the normal and malignant state have 
been described and applied.  Starting with normal hematopoiesis, we studied a unique but 
important way that this normal state can be insulted, and in turn, discover a potential therapeutic 
strategy for mitigating these damages to bone marrow cells.  Much is known about the damaging 
effects radiation, however the major unanswered question in radiation epidemiology, is not 
whether radiation causes cancer, but what the level of risk is following low dose rate 
exposures.185 As seen from the recent Fukushima nuclear reactors accident, low dose exposures 
of radiation received over time are likely to impact large communities, but the risks are still 
unknown.  We showed that protracted low dose-rate radiation exposure affects hematopoiesis, 
and that chloroquine can be a potential prophylaxic treatment by enhancing engraftment of 
myeloid progenitors to maintain hematopoiesis.  Our whole animal model can also be used to 
further study the effects of protracted low dose-rate radiation on other organ systems.   
 
Learning about how normal hematopoiesis is perturbed can shed light on how malignant 
hematopoiesis arise and in turn, how to interrupt the malignant transformation process.  To better 
understand disease progression, we generated a novel mouse model of myeloid disease 
progression and showed that Hedgehog signaling, a developmental signaling pathway that has no 
impact on normal adult hematopoiesis has a role to play in myeloid disease acceleration initiated 
by the FLT3-ITD oncogene.  Importantly, there are small molecule inhibitors against both the 
Hedgehog and FLT3 signaling pathways; we showed that combinatorial therapy using these 
inhibitors could reduce leukemic growth and improve overall survival, suggesting a viable 
therapeutic strategy for patients with advanced FLT3-ITD AML. 
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Future directions: 
Future studies could include an investigation into the mechanism of chloroquine protection 
against low dose-rate radiation.  It is likely that chloroquine acts by multiple mechanisms in vivo, 
and it is possible that additional protective functions including those mediated by the bone 
marrow microenvironment also contribute to its activity.  It is also conceivable that the survival 
benefit associated with chloroquine may be associated with an increased accumulation of genetic 
alterations and mutations.  Therefore, further investigation of chloroquine’s action that include 
both ATM-mediated and independent processes is warranted.  A potential side effect of 
chloroquine in combination with radiation may be cutaneous desquamation has been reported.186 
We did not observe skin reactions in the mice treated with chloroquine and low dose-rate 
radiation.  Nevertheless, given its tolerability and low cost, chloroquine may serve as a readily 
accessible agent drug for protection from LDR radiation injury.  Our study using mice could also 
be expanded to include larger animals such as dogs, pigs and chimpanzees.  Furthermore, the 
efficacy of chloroquine in radioprotection after radiation exposure should also be examined.   
 
From our pre-clinical studies with Hh and FLT3 inhibitors, a clinical trial involving combinatorial 
therapy of Sorafenib and IPI 926 in patients with advanced or relapsed FLT3-ITD AML could be 
initiated.  Other FLT3 inhibitors currently in development can also be tested in combination with 
IPI 926.  The rapid advancement of Smo inhibitors into clinical development has provided 
exciting results in mutation-driven tumors with activated Hh signaling and led to the approval of 
vismodegib as a first-in-class treatment for advanced BCC, but it has also revealed that the 
clinical application of single-agent Smo inhibitors might not be as broad as was initially expected.  
Tumors that have shown clinically meaningful responses are either very rare (such as 
medulloblastoma) or rarely require systemic therapy (such as BCC).  BCC is almost exclusively 
dependent on Hh signaling, and not surprisingly, these tumors are exquisitely sensitive to Smo 
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inhibition.  Nonetheless, a number of questions remain regarding the optimal dosing schedule, the 
optimal treatment duration and whether a complete cure is achievable.   
 
Notably, all these negative trials included unselected patients.  Given the encouraging preliminary 
results in selected patients with Hh-activated medulloblastoma, it is important to invest more 
effort in the exploration of the evolving knowledge of crosstalk between Hh signaling and other 
oncogenic pathways.  Given the emerging complexity of Hh pathway activation in cancer, it will 
be important to differentiate Smo-dependent from Smo-independent canonical or noncanonical 
pathway activation.  A detailed understanding of the mechanism leading to GLI activation in each 
tumor will allow for selection of the appropriate Hh pathway inhibitor and, in cases where 
crosstalk between Hh signaling and other oncogenic pathways exist, the optimal combination 
partner.  Furthermore, mouse models increasingly hold tremendous potential for cancer therapy, 
given the sophistication of genetic manupulation techniques as well as commercial availability of 
these murine systems, and can greatly facilitate translating research findings into the clinics.187 
Further work on the potential interaction of FLT3 tyrosine signaling pathways and other signaling 
pathways could also be explored.   
 
Finally, the potential of an epithelial-mesenchymal-transtition (EMT) like program responsible 
for transformation in leukemogenesis could be further explored.  Although the EMT theory has 
been evidenced from solid tumors that have the ability to metastasize, the underlying core 
machinery that drives this transition, and not the overt phenotype, may fuel the transformation of 
cancers in general.188 Hematopoiesis and its malignancies can be a great system to use to 
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